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Abstract 
EXAMINING THE ASSOCIATION OF MEDICATION COMPLEXITY WITH 
HEALTH-RELATED QUALITY OF LIFE IN OLDER ADULTS RECEIVING 
COMMUNITY-BASED LONG TERM SERVICES AND SUPPORTS 
by 
Claudia A. Beck 
Adviser: Dr. Kathleen Nokes 
While the complexity of a medication regimen is a concern for all individuals, it is of 
significant concern for community-dwelling older adults who often require multiple 
medications to treat chronic health problems.  Health related quality of life (HRQoL) has 
been identified as a key quality outcome measure when assessing care of older adults, 
particularly those with long-term care needs.  Although the use of multiple medications 
has been widely explored in the literature, there is a paucity of data regarding the 
combination of several medication-related factors (number of active medications, 
therapeutic drug class, and medication regimen complexity) and HRQoL in older adults. 
Wilson and Cleary's health-related quality of life conceptual model was the theoretical 
framework used to guide this study. This secondary analysis examined the relationship 
among the number of active medications, the number of therapeutic drug classes, and 
medication regimen complexity and HRQoL in community-dwelling older adults (68% 
Hispanic, 75% female) who were recent recipients of home and community-based 
services (H&CBS).  The subjects in this study (N =123) were enrolled in a large, multi-
site study (N=470) (R01-AG025524, PI, M. Naylor). Medication-related data were 
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vi 
obtained from medical charts, counted to include the active number of medications as all 
prescription and over the counter drugs (mean =9.3), and a therapeutic drug class tool 
(mean =4.9) measured the number of distinct therapeutic drug classes included in a 
medication regimen. Medication regimen complexity (mean = 20.6) was measured using 
the Medication Regimen Complexity Index (MRCI). The Medical Outcomes Study Short 
Form (MOS SF-12 v2) physical (PCS) and mental component scores (MCS) measured 
HRQoL. After controlling for age, gender, education, race, ethnicity, marital status and 
cognitive status, it was determined that the number of active medications (β coefficient -
.497, p=.012) was a key predictor of physical health-related quality of life, while 
therapeutic drug class and medication regimen complexity were not associated with 
either physical or mental health-related quality of life. The number of medications 
impacts on physical health-related quality of life but the directionality of that relationship 
is not clear; there were no significant effects on mental health-related-related quality of 
life and medication-related variables. 
Keywords: Older adults, active medications, therapeutic drug class, medication regimen 
complexity, community-based long term services and supports. 
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Chapter I 
Research Objective 
 "What will this drug do for me?" asks the patient. "Well" replies the physician, "a 
 rigorous systematic review of randomized trials shows that etidonate will improve 
 measures in your bone density." "I'm not impressed," replies the patient, "unless 
 those stronger bones improve my quality of life" (Guyatt et al. 2007, p.1232). 
Background of the study 
Medications are often used to cure and alleviate disease, improve quality of life, 
and lengthen life expectancy (Gelland, Grenard, & Marcum, 2011). The Institute of 
Medicine (IOM) (2013) has identified health-related quality of life as a national priority 
for older adults and it has emerged as an important and appropriate construct for older 
recipients of long-term services and supports. Health-related quality of life highlights 
aspects of the older adult's well-being affected by changes in their health status and the 
quality of their health care.  Health-related quality of life is an individual's perception of 
the impact of a disease and its treatment on well being (Sousa & Kwok, 2006). Cella 
(1995) described health-related quality of life as “the extent to which one’s usual or 
expected physical, emotional and social well-being are affected by a medical condition or 
its treatment” (p.73).  
The World Health Organization (WHO) defines health as "a state of complete 
physical, mental, and social well-being and not merely the absence of disease or 
infirmity" (WHO, 1948). This conceptualization of health into physical, mental and 
social components has strongly shaped general health frameworks for more than 60 years 
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(Fryback, 2010). In alignment with the WHO's definition of health, the theoretical 
framework of health-related quality of life is fundamentally based on a multidimensional 
view of health that includes physical, psychological, social functioning and well-being 
(Borglin, Jakobsson, Edberg, & Hallberg, 2005; Thompson, Zack, Krahn, Andresen, & 
Barile, 2012). The central components of health-related quality of life are required for an 
individual to meet the daily demands of life (Achat, Levine, Coakley, & Colditz, 1998) 
and have become an important outcome measurement in public health as well as in 
clinical research and practice (Moriarty, Zack, & Kobau, 2003). This is due in part to the 
advancement in treatment options and technology, particularly in the areas of chronic 
disease treatment and management in older adults (Chen, Li & Kochen, 2005).  
 As the leading causes of death shift from acute illness to chronic disease,  health-
related quality of life is a significant outcome measure when determining the impact and 
effectiveness of clinical interventions and treatment including medications (Chenet al., 
2005; Cleary & Howell, 2007; Francic & Jiang, 2006; Walters, Munro, & Brazier, 2001).  
This outcome is important because the goals of treatment in chronic disease is to improve 
function, slow disease progression, and reduce suffering. The aim is to reduce the 
negative impact on health-related quality of life arising from treatment in older adults 
rather than to achieve a cure (Degl'Innocente et al., 2002; Williams, 2002).  As 
individuals age, there is a greater likelihood to experience multiple health symptoms such 
as pain and fatigue. These health complaints are relevant to nursing care through early 
assessment of health symptoms that potentially affect a decline in health-related quality 
of life (Borglin et al.,2005; Zubritsky et al.,2012).  
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At any given time four out of five American older adults will use multiple 
prescription medications, over-the-counter drugs or dietary supplements with 40% taking 
5 to 9 medications and 18% taking 10 or more medications within eight or more 
therapeutic drug classes (Classen, Mann, Wu, & Tomita, 2004; Institute of Medicine 
(IOM), 2006; Slone Survey, 2006).  In the United States, approximately 10,000 people 
turn age 65 every day and by 2030, approximately one out of every five Americans will 
be aged 65 years and older (Centers for Disease Control and Prevention, [CDC], 2011).  
As life expectancy continues to increase and more drugs become accessible to reduce the 
effects of chronic illness, the utilization of prescription medications will also increase 
(Masoodi, 2008) particularly in older adults living in the community.    
  Community-dwelling older adults are the largest consumers of medications today 
with approximately 20% actively taking ten or more different medications at a given time 
(LeCouteur, Ford, & McLachlan, 2010; Slone Survey, 2006; Steinman & Hanlon, 2010).  
The use of ten or more medications can easily be reached by following clinical practice 
guidelines for a small number of concurrent conditions such as diabetes, hypertension, 
chronic obstructive pulmonary disease and osteoarthritis (Boyd, et al., 2005; Slone 
Survey, 2006). Medication therapy is more complex in older adults due to age-associated 
physiologic changes, multiple co-morbidities, having numerous providers, using more 
than one filling pharmacy, multiple dosing frequencies (Elliot, O’Callaghan, Paul, & 
George, 2013; Planton & Edlund, 2009) using several forms of medications, for example 
tablets, inhalers or injections (Boparai & Korc-Grodzicki, 2011; Paquin et al., 2013).  
 The use of multiple medications, also known as polypharmacy, contributes to 
lower adherence, greater risk of falls (Tinetti et al., 2014), adverse drug events, increased 
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risk of medication errors, increased emergency room visits, hospitalizations, decline in 
cognitive status and nursing home admissions all of which result in increased health care 
costs (Boparai & Korc-Grodzicki, 2011; Francic & Jiang, 2006; Fulton & Allen, 2005; 
Jyrkka, Enlund, Korhonen, Sulkava, & Hartikainen, 2009; IOM, 1999; Preskorn, et al., 
2005; Steinman & Hanlon, 2010).  If medication-related problems were ranked as a 
disease by cause of death, it would be estimated to be the fifth leading cause of death in 
the United States, making medication management in older adults a significant concern 
(Ballentine, 2008; Slabaugh et al., 2010).   
 Despite the use of multiple medications being a significant concern in older 
adults, a commonly accepted definition or consistent cut-point for polypharmacy has yet 
to be established (Hajjar, Cafierio, & Hanlon, 2007; Slabaugh, Maio, Templin & 
Abouzaid, 2010). Although operational definitions of polypharmacy have varied 
significantly and gaining consensus on the definition is still lacking, a range of three to 
five drugs has been frequently used (Hanlon, Schmader, Ruby & Weinberger, 2001; 
Jyrkka, Enlund, Korhonen, Sulkava, & Hartikainen, 2009).  However variation is seen , 
for example, Preskorn et al. (2005) defined polypharmacy to literally mean taking two or 
more prescription medications daily. 
 When evaluating polypharmacy, therapeutic drug classification is important to 
consider because of the potential for increased adverse drug events to occur (Hajjar,       
et al., 2007; Willson, Greer, & Weeks, 2014). A large national survey identified the most 
commonly used prescriptions medications in community-dwelling older adults in the 
cardiovascular, endocrine and antilipidemic drug classes (Kaufman, Kelly, Rosenberg, 
Anderson, & Mitchell, 2002).  A study conducted by Gurwitz et al. (2003) found 1523 
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adverse drug events were associated with a wide range of different therapeutic drug 
classes with cardiovascular drugs most frequently cited (26%) followed by antibiotics 
(14.7%) and non-opioid analgesics (11.8%).   
 Along with the use of a wide range of therapeutic drug classes, older adults are 
frequently prescribed medications in varying doses, frequencies and routes of 
administration (Steinman, et al., 2006).  As a result, the complexity of the medication 
regimen increases as the number of medications increase (George, Phun, Bailey, Kong & 
Stewart, 2004). The most frequent reasons for medication errors have been linked to the 
characteristics of complexity of an individual's medication regimen (administration, 
frequency of dosing, and symptoms prompting the need for medications) (George et al., 
2004). Medication regimen characteristics have had significant impact on patient 
outcomes (Elliot, 2012; George, et al., 2004).  A study by Wolf et al. (2011) found 
increased medication regimen complexity led to significant intrusion in patients' daily 
lives. Nurses can make a significant impact in reducing the effects of medication 
complexity in older adults and are in a unique position to modify the adverse 
consequences of complex medication regimens (Frazier, 2005; Liu, Manias, & Gerdtz, 
2011). 
 Generally, the goals of medication therapy for older adults are to treat disease, 
diminish pain and suffering, avert life-threatening complications due to chronic illness, 
lengthen life expectancy and ultimately improve quality of life (Gelled, et al., 2011).  To 
accomplish these goals, benefits and risks of optimal medication therapy must be 
balanced against health-related quality of life factors for older adults with chronic illness 
requiring long-term care needs (Cleary & Howell, 2007).  Nurses often evaluate the 
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effectiveness of drug therapy through assessment of symptoms including physical or 
biochemical markers of disease activity (Griffiths, Johnson, Piper, & Langdon, 2004).  
These evaluation strategies however are not sufficient as they do not reflect the multiple 
determinants of health that could be revealed through health-related quality of life 
measurement (Degl'Innocenti et al., 2004). 
 An estimated six million older adults receive long term services and supports 
(LTSS) in their own homes, assisted living facilities or nursing homes (Abbott, Bettger, 
Hanlon, & Hirschman, 2012; Kaye, Harrington, & LaPlante, 2010). Older adults with 
chronic illness often require long-term care and the number of older adults who will be in 
need of long-term services and supports in the United States will more than double by 
2030 (Knickman & Snell, 2002). A person in need of LTSS requires human assistance 
with activities such as bathing, dressing or eating or may need assistance with preparing a 
meal, shopping or using a telephone as a result of physical, mental, or emotional 
problems (Agency for Healthcare Research & Quality, [AHRQ], 2001). A wide range of 
services are offered and  maintained over an extended period of time to people  with 
chronic health care needs and functional deficits (Reinhard, Kassner, & Houser, 2011).  
Physical, functional and cognitive decline in combination with multiple co-morbidities 
underscore the importance of assessing health-related quality of life of individuals in 
LTSS (Zubritsky et al., 2012).  
Statement of the Problem 
 Is there an association of the number of active medications, therapeutic drug class, 
and medication regimen complexity with health-related quality of life in community-
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dwelling older adults receiving home and community-based long term services and 
supports in Washington Heights between 2007 and 2008? By examining three variables 
related to medication use, specifically the number of active medications, therapeutic drug 
class and medication regimen complexity, this study tested whether specific medication 
constructs were associated with health-related quality of life. 
Definition of Terms 
 Active medications. Active medications were defined as the number of 
medications a subject was taking and included both prescription and over the counter 
medications. Active medications were measured according to the medication list in the 
electronic health record at the date of enrollment (see Appendix A) on the Health Related 
Quality of Life Chart Abstract Tool (Naylor, 2004).  
 Cognitive status. Any mental process that involves symbolic operations to 
include perception, memory, creation of imagery, and thinking and also includes 
awareness and judgment capacity (McGraw-Hill Concise Dictionary of Modern 
Medicine, 2002) and was measured by the Mini Mental State Exam (MMSE) (Folstein, 
Folstein, & McHugh, 1975). (see Appendix B).   
 Community-dwelling.  Individuals who reside at home and are not in an assisted 
living facility or nursing home (Ganz et al., 2006) and was measured by the organization 
providing the home and community-based services (see Appendix C) (Naylor, 2004).  
 Health-related quality of life.  Health related quality of life is a health-focused 
quality of life concept that includes characteristics of quality of life impacting health to 
include physical, mental and functional health and is viewed from the individual’s 
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perception of their physical and mental health (McHorney, 1999; Zubritsky et al., 2012). 
Health-related quality of life was measured by the Medical Outcomes Study Short Form 
(SF12 - v2) (see Appendix D) which provides a physical component summary (PCS) and 
a mental component summary (MCS) that measures self-reported physical and mental 
health ratings (Ware, Kosinski, & Keller, 1995).   
 Long term services and supports (LTSS).  LTSS is a broad range of supportive 
services required by individuals who have reduced capacity for self-care as a result of 
physical, cognitive or mental disability or illness (Reinhard et al., 2011).  Admission into 
an LTSS setting was measured by the classification (e.g. Home and Community-based 
{H&CBS}, Assisted Living Facility {ALF}, or Nursing Home {NH}) of the organization 
that enrolled the older adult (see Appendix C) in the Health Related Quality of Life Chart 
Abstract Tool (Naylor, 2004). 
 Medication regimen complexity.   Medication regimen complexity is 
conceptually related, but not equal to the count of medications and takes into account 
several aspects of medication regimens to include dosage form (e.g. tablet, liquid), dosing 
frequency (e.g. once a day, twice a day), and additional directions (e.g. crush pill, take 
with food) (George et al., 2012) and was measured by the Medication Regimen 
Complexity Index (MRCI) (see Appendix E) (George et al., 2004).  
 Therapeutic drug class.  Is the classification system of drugs into different 
groups according to the organ or system on which they act and their therapeutic, 
pharmacological and chemical properties (World Health Organization Collaborating 
Center [WHOCC], 2011). Therapeutic drug class was measured by the number of distinct 
therapeutic drug classes present in the active medication list as defined by the 12 
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therapeutic drug classes (see Appendix F) categorized in Drug Facts & Comparisons 
2013. 
Delimitations 
This study included adults who were:  
1) enrolled in the primary study Health Related Quality of Life: Elders in Long Term 
Care  (R01AG025524-01A2, PI, M. Naylor) during 2007 and 2008. 
2) age 60 years and older  
3) recently (within 60 days) recipient of community-based LTSS in New York, N.Y. 
Theoretical Rationale 
 Most experts strongly recommend the use of a multidimensional conceptual 
model to guide the assessment of health-related quality of life (Ware, 1994; Wilson & 
Cleary, 1995). Wilson and Cleary (1995) developed a conceptual model (see Figure 1) of 
health-related quality of life that addresses patient outcomes that provided a linear 
depiction linking five domains of physiological variables, symptom status, function, 
general health perceptions, and health-related quality of life (Nokes et al., 2011; Wilson 
& Cleary, 1995). Prior to this conceptualization, there was little research that explored the 
relationship between clinical variables and measurement of the multidimensional concept 
of health-related quality of life (Chen et al., 2005; Wilson & Cleary, 1995). The model 
(see Figure 1.1) focuses on the relationships among several domains of health-related 
quality of life including: a) biological function and physiological factors; b) symptom 
status; c) functional status; d) general health perceptions; and e) overall quality of life. 
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There are two additional factors included in this model: a) characteristics of the 
individual, and b) characteristics of the environment which impact on all of the domains 
(Wilson & Cleary, 1995).   
 
 
 
 
 
 
 
 
 
Figure 1.1.  Wilson and Cleary’s Health-related quality of life conceptual model. 
Reproduced with permission from Wilson I.B., & Cleary, P.D. (1995). JAMA, 273, 59-
65. Copyright © (1995) American Medical Association. All rights reserved. (see 
Permission Appendix L). 
Individual characteristics can be defined as distinguishing traits of a human being 
to include measures of age, gender, education, race, ethnicity, marital status and cognitive 
status (Naylor, 2004; Wilson & Cleary, 1995). Environmental characteristics include 
interaction with providers, characteristics of the service delivery system, and the 
structural features of the physical environment. The characteristics of the individual and 
the environment are overarching factors that affect all of the five domains of overall 
MEDICATION COMPLEXITY AND HRQOL                                                                                                        
 
 
 
11 
quality of life (Nokes, et al. 2000). For the purpose of this study individual characteristics 
included age, gender, education, race, ethnicity, marital status and cognitive status.   
The intent of the health-related quality of life model was to unite the biomedical 
and social science paradigms to make the connection between the mind and body (Sousa 
& Kwok, 2006; Wilson & Cleary, 1995).  The biomedical paradigm’s focal point relates 
to the causative and pathological factors with outcomes measured within the clinical 
aspects of biological and physiologic domains (Wilson & Cleary, 1995).  The social 
science paradigm’s focal point relates to the domains of environment, functioning and 
overall well-being with the outcomes measuring intricate behaviors and feelings (Wilson 
& Cleary, 1995).  The key goal of clinical care is to improve patient outcomes. Wilson 
and Cleary’s (1995) conceptual model of health-related quality of life links what is 
occurring on a biological, biomedical level to the impact on individual’s symptoms, 
functional status, general health perceptions and overall quality of life.  
Biological function centers on cells, organs and organ systems. Examples include: 
a) diagnoses such as inflammatory bowel disease or small cell lung cancer; b) laboratory 
values to include creatinine, blood urea nitrogen, glucose, and serum hemoglobin; c) 
measures of physiological function to include pulmonary function tests and physical 
examination findings such as splenomegaly or systolic ejection murmur; d) number and 
types of medications; e) height and weight; and f) medical conditions (Naylor, 2004; 
Wilson & Cleary, 1995).  Medical conditions are often treated with medications and 
biological function was measured by the total number of active medications, therapeutic 
drug classes and medication regimen complexity (see Table 1.1) in this study since 
medications may impact on disorders of different biological systems.  
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 Wilson and Cleary’s (1995) conceptual model of health-related quality of life has 
been useful in creating strategies and instruments that identify and measure variables 
associated with health-related quality of life and hence provide the opportunity to 
improve outcomes in this domain (Sousa & Kwok, 2006; Wilson & Cleary, 1995). 
Wilson and Cleary recommended assessing overall quality of life with general measures 
to determine how happy or satisfied a person is with their life as a whole (Sousa & Kwok, 
2006).  The Medical Outcomes Study Short Form (MOS SF-12 v2) (see Appendix D) 
provides an example of how assessment of health-related quality of life has been 
integrated as part of an overall health survey to measure and determine outcomes (Brazier 
& Roberts, 2004; Borglin et al., 2005; Gandhi et al., 2001; Jones, Jones & Miller, 2004; 
Larson, Schlundt, Patel, Beard, & Hargreaves, 2008; Montazeri et al., 2011; Sousa & 
Williamson, 2003).                               
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDICATION COMPLEXITY AND HRQOL                                                                                                        
 
 
 
13 
Table 1.1              
Conceptual-Theoretical-Empirical-Structure                                                                                                                                  
Wilson and Cleary's  
Health-related 
quality of life 
conceptual Model 
Biological  and 
physiological 
function 
Health-related 
quality of life 
Characteristics 
of the 
individual 
Theoretical Linkages              Active medications, 
therapeutic drug 
class and  
medication regimen 
complexity  
Self reported 
mental and 
physical  health 
scores 
Age , gender, 
education, race, 
ethnicity, 
marital status, 
and cognitive 
status 
Empirical Indicators              Number of active 
medications,  
Therapeutic Drug 
Classification  
Medication 
Regimen 
Complexity Index 
tool (MRCI) 
Medical Outcomes 
Study Short Form 
(SF-12 v2) Mental 
Component Score 
(MCS) and 
Physical 
Component Score 
(PCS) 
1)Medical 
Record 
Abstract -
Demographic 
data 
 
2) Mini Mental 
State Exam 
(MMSE) 
 
Research questions and hypotheses 
 Research question 1. Is there an association between the number of active 
medications and physical and mental health-related quality of life of older adults 
receiving community-based LTSS before and after controlling for age, gender, education, 
race, ethnicity, marital status and cognitive status? 
 H1a: The number of active medications will be associated with physical health-
related quality of life in of older adults receiving community-based LTSS. 
MEDICATION COMPLEXITY AND HRQOL                                                                                                        
 
 
 
14 
 H1b: The number of active medications will be associated with mental health-
related quality of life in of older adults receiving community-based LTSS. 
 Research question 2.  Is there an association between the number of therapeutic 
drug class and physical and mental health-related quality of life of older adults receiving 
community-based LTSS before and after controlling for age, gender, education, race, 
ethnicity, marital status and cognitive status? 
 H2a: The number of therapeutic drug classes will be associated with physical 
health-related quality of life in older adults receiving community-based LTSS. 
 H2b: The number of therapeutic drug class will be associated with mental health-
related quality of life in older adults receiving community-based LTSS. 
 Research question 3. Is there an association between medication regimen 
complexity and physical and mental health-related quality of life in older adults receiving 
community-based LTSS before and after controlling for age, gender, education, race, 
ethnicity, marital status and cognitive status? 
 H3a: Medication regimen complexity will be associated with physical health-
related quality of life in older adults receiving community-based LTSS. 
 H3b: Medication regimen complexity will be associated with mental health-
related quality of life in older adults receiving community-based LTSS. 
Study Significance 
This study contributes: (a) to understand medication effects on health-related 
quality of life in a racially and ethnically diverse population of older adults, (b) to 
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advance knowledge of medication regimen complexity assessment, and (c) to the body of 
evidence in nursing science to improve health care health-related quality of life outcomes 
for older adults.  Medications are vital to treat many chronic illnesses and maintain health 
and quality of life for older adults. However there are significant negative outcomes 
related to medication use. There is emerging evidence that older adults with multiple co-
morbidities vary in the amount of value they place on health outcomes such as longer 
survival and prevention of specific disease events and the risk of medication-related 
adverse effects that they are willing to endure (Roth & Levy, 2005; Tinetti, Bogardus, & 
Agostini, 2004).  Many efforts to evaluate the quality of medication use focuses on high-
risk drugs, appropriate management of chronic disease or a set of pre-determined quality 
indicators of medications rather than the patient themselves (Cleary & Howell, 2007; 
Roth, Weinberger & Campbell, 2009).  Nurses can provide comprehensive assessment 
and interventions to support older adults to safely and appropriately manage their 
medication regimens that provide cost-effective care and improvement in their health-
related quality of life (Marek & Antle, 2008).  
 Older adults, and in particular those adults who are non-English speaking, have 
multiple co-morbidities, or cognitive impairments, are often excluded from evidence-
generating research (Classen et al., 2005; Tinetti, Bogardus, & Agostini, 2004). In 
addition, the literature regarding health-related quality of life in community-dwelling 
older adults as it relates to medications factors (number of active medications, therapeutic 
drug class, and medication regimen complexity) is sparse. This study contributed to the 
evidence regarding medication-related factors and health-related quality of life in a small 
sample of predominately Hispanic older adults.  
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Chapter II 
Review of Literature 
The purpose of this study was to examine the relationships of medication-related 
factors (the number of active medications, the number of therapeutic drug classes, and 
medication regimen complexity) with health-related quality of life in older adults 
receiving home and community-based services (H&CBS). The following review of the 
literature represents the evidence relevant to this research study, namely, health-related 
quality of life, a health-related theoretical framework, health-related quality of life in 
older adults and Hispanics, multiple medication use in older adults, therapeutic drug class 
use, medication regimen complexity and health-related related quality of life and 
medication use.  
Health-related quality of life  
 According to the WHO definition of quality of life, health is considered to be an 
important domain that contributes to the overall quality of life (Singh & Dixit, 2010).  De 
Haes and van Knippenberg (1985) noted that the study of quality of life as it relates to 
health provides a greater understanding of a patient's response to a disease as well as to 
prescribed treatments. To better address this issue, the concept of quality of life in the 
context of health and illness is known as health-related quality of life. The term was 
intended to focus on the impact of health, illness and treatment on quality of life (Ferrans, 
Zerwic, Wilbur & Larson , 2005; Singh & Dixit, 2010).   The concept of quality of life 
was originally used in cancer treatment by nurses and physicians to explain the 
distinction between the medical and technical components of care and other aspects of 
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patient care (De Haes & van Knippenberg, 1985).  When confronted with the suffering of 
patients directly, they focused on paying more attention to supportive care or quality 
versus the duration of survival.  
 In the last 30 years, assessment of health-related quality of life has become more 
relevant in health care particularly in the realm of health and illness, with the patient 
considered to be an active participant in their care and their choice of treatment options 
(Ferrans, Zerwic, Wilbur & Larson, 2005).  Research conducted on several chronic 
diseases has emphasized the relevance of evaluating health-related quality of life as part 
of clinical practice to determine the effects of medical and community-based 
interventions (Mickle et al., 2011; Singh & Dixit, 2010). Corace and Endler (2003) noted 
that assessment of health-related quality of life is significant for a number of reasons; 
specifically to provide clinicians with information related to the impact of disease and 
illness on an individual’s daily life, effects of treatments on their health-related quality of 
life and the ability to evaluate and measure the effects of interventions on health-related 
quality of life (Corace & Endler, 2003; Ferrans et al., 2005) from the patient's perspective 
(Sousa & Kwok, 2006).  
Theoretical Framework 
 Wilson and Cleary (1995) developed a conceptual model of health-related quality 
of life to address patient outcomes.  The model has been widely used in different 
populations to include patients living with HIV/AIDS, Parkinson’s disease and cancer 
(Chrischilles, Rubenstein, Voelker, Wallace, & Rodnittzky, 2002; Nokes et al., 2000, 
2011; Sousa & Williamson, 2003). Considerable work has been done to develop self-
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administered health-related quality of life measures that can be scored through the use of 
subscales that encompass pertinent predictors. Archat et al. (1998) described the 
fundamental elements of health-related quality of life as functional status, general health 
and well-being, and proposed that these elements are required for a person to meet the 
daily demands of life and therefore satisfy their needs and desires. This description of 
health-related quality of life is compatible with the Medical Outcomes Study Short Form 
-12 (SF-12) (MOS SF-12) which aims to measure functioning, well being and general 
health status (Ware, Kosinski, & Keller, 1996).  
 The MOS SF-12 was used by Sousa & Williamson (2003) to study the 
relationship between symptom status and health-related quality of life utilizing the 
Wilson and Cleary conceptual model. The sample (n=99) included emergency room 
patients with a diagnosis of gastrointestinal bleeding with a mean age of 57.8 years with 
62.6% being male. The Short Form 12 (SF-12) physical component scores (PCS) and 
mental component scores (MCS) were used to measure health-related quality of life along 
with a 15-item symptom checklist developed and validated for that study at baseline and 
one month follow-up. Regression analysis controlling for age, gender, hematocrit, and 
co-morbidities was used to examine the relationship between symptom status and health-
related quality of life. Results showed that baseline symptom status contributed 20.2% 
(R²change =.202, p=0.001) of the variance explained in the baseline PCS score and 
23.2% (R²change =.232, p= 0.001) at one month follow-up. Symptoms status also 
explained variance in baseline and follow-up MCS scores (R²change =.098, p=0.001 and 
R²change =.292, p=0.001, respectively). This research suggested that symptom status 
was a key predictor to health-related quality of life. 
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Health-related quality of life in older adults 
 Predictors of health-related quality of life may be identifiable in older adults. This 
is of particular importance as the demographic profile in the United States shift towards 
old age with greater longevity, as adults over the age of 65 years comprise a growing 
proportion of the population with major use of health care (Walters, Munro, & Brazier, 
2001). As a result of this shift assessing health-related quality of life in older adults has 
become an increasingly important component to address (Hickey, Barker, McGee, & 
O’Boyle, 2005). Older adults have a greater probability of having numerous co-
morbidities and multiple health complaints that are not curable, and therefore greatly 
affect their health-related quality of life. 
 Similarly, Borglin et al. (2005) described how health complaints and selected 
characteristics of age, gender, living situation, marital status and socio-economic status 
predicted overall and health-related quality of life in older adults.  The SF-12 was used to 
measure health-related quality of life with women reporting lower health-related quality 
of life. The SF-12 PCS mean (p=0.03) was 37.7 for females and 40.6 for male and a 
Mental Component Score (MCS) mean (p=0.005) of 51 for females and 54 for males.  
Self-reported health problems such as pain (p=0.001), mobility problems (p=0.001) and 
fatigue (p=0.001) significantly predicted lower physical health related quality of life. The 
findings indicate that many common health issues occurring at the same time can 
negatively impact older adults' health-related quality of life and may interact with each 
other rather than in isolation.  
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 In addition, when compared to the general population, health-related quality of 
life in older adults can be a significant indicator of health status with prognostic 
implications (Otero-Rodriquez et al., 2010).  Otero-Rodriguez et al., (2010) examined 
whether changes in health-related quality of life could predict ensuing mortality among a 
Spanish population aged 60 and older. The findings demonstrated that changes in health-
related quality of life are predictive of mortality in older adults. The significance of 
decreased health-related quality of life in older adults should trigger awareness of a 
worsening prognosis and an assessment of possible causes of decline.  
  To further advance the assessment of health-related quality of life in older adults, 
Zubritsky et al. (2013) adapted the Wilson and Cleary model within the context of older 
adults who require long term services and supports (LTSS). To create a more rigorous 
model, functional status domain now includes cognition and LTSS use and behavior were 
added to environmental characteristics. The adaptation of this evolving model is more 
reflective and relevant to measure the characteristics of this population, particularly when 
cure is not the expected outcome, but rather the management of symptoms, chronic 
disease and cognitive decline (Zubritsky et al., 2013).  
Health-related quality of life and Hispanics 
 While increased awareness of declining health-related quality of life is important 
for all older adults,  few studies have examined health-related quality of life by race and 
ethnicity and most have focused on only one measure of health-related quality of life 
(Chowdhury, Balluz, & Strine, 2008).  Many psychometric measures for health-related 
quality of life instruments were created utilizing ethnically homogeneous subjects, 
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making the suitability of administrating them to more ethnically diverse samples 
questionable (Corliss, Nicholas, & Nokes, 2001). Most attempts to adapt health-related 
quality of life measures, particularly the Short Form-36 (SF-36), across diverse minority 
groups have been through the utilization of language translation (Regidor, Barrio, de la 
Fuente, Domingo, Rodriguez, & Alonso, 1999; Tann, 2005). Hispanics are comprised of 
culturally diverse sub-groups which may influence views of illness and therefore, 
responses to questions related to health-related quality of life (Gonzalez-Burchard et al., 
2005; Porter, Vijil, Unruh, Lora, & Lash, 2010). 
 In addition to being culturally diverse, Hispanics are the largest and fastest-
growing minority population in the United States today (U.S. Census Bureau, 2011). In 
2010, there were 50.5 million Hispanics in the United States (US Census Bureau, 2011).  
Hispanics comprised 16.3% of the population, and the largest Hispanic subgroup among 
this population consisted of Mexicans (63%) The second largest group was Puerto Rican, 
comprising 9.2%, Cubans account for 3.5% and Dominicans account for 2.8% of the total 
Hispanic population in the United States (Ennis & Albert, 2010). Yet there is a scarcity of 
data regarding health-related quality of life in minorities and in particular, in Hispanics 
(Porter et al., 2010). 
 Porter et al., (2010) highlighted certain issues in data collection that impact 
health-related quality of life results for Hispanics. For example one issue, item response 
bias, describes bias due to extreme response style with responses tending to collect 
toward the extreme choices. Population-based studies of health-related quality of life 
among people in the United States have found that Hispanics are more apt to report fair to 
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poor health-related quality of life when compared with whites (Zahran, Kobau, Moriarity, 
Zack, Holt, & Donehoo, 2005). 
 Likewise, Hayes et al. (2011) examined disparities in health-related quality of life 
among adults with self-reported coronary heart disease (CHD). Using data from the 2007 
Behavioral Risk Factor Surveillance System, disparities in health-related quality of life 
were examined using the unhealthy days measurements for adults who self-reported 
coronary heart disease (6.1% of surveyed population). The study findings demonstrated 
that Hispanics were more apt than non-Hispanic whites to report fair or poor health status 
(Adjusted odds ratio[AOR], 1.5). 
 The literature regarding Hispanics and health-related quality of life measurement, 
although limited in volume, highlights the importance of selecting instruments that use 
unbiased terms that are culturally relevant to all Hispanic sub-groups. The sample for this 
secondary analysis was primarily recruited from a community in which the U.S. Census 
data reports that 71% are of Hispanic ethnicity (U.S Census, 2011). 
Multiple medication use in older adults 
 Medication-related problems are common, expensive and often avoidable in older 
adults and can lead to poor health outcomes (American Geriatric Society, 2012a). 
Polypharmacy, the concurrent taking of many medications, has been well documented in 
the United States (Fulton & Allen, 2005; Jyrkka et al., 2009) and can be a significant 
concern for improving quality of care for older adults. Medication therapy in older adults 
presents several challenges due to age-related physiologic changes, numerous co-
morbidities, use of multiple medications to include prescription, over the counter and 
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herbal supplements, and multiple prescribing providers (Boparai & Korc-Grodzicki, 
2011).  Medications can play an essential role in maintaining the health of older adults 
who frequently experience the burden of multiple chronic diseases with acute episodes.    
 The burden of multiple chronic diseases often requires taking multiple 
medications concurrently, leading to an increase risk of an adverse drug event 
(LeCouteur, Ford, & McLachlan, 2010).  This has been defined as "an injury resulting 
from the use of a drug" (Gurwitz et al., 2003, p.1109). In a study by Laroche et al. (2007) 
the risk of adverse drug events were shown to increase 3.4 fold when older adults took 4-
6 medications, 4.6 fold when using 7-9 medications, and 5.9 fold when 10 or more 
medications were used.  Delafuente (2003) reported an increase risk in the potential for 
drug to drug interactions as the number of prescribed medications increased,  showing a 
probability of drug interactions rising to 50% with five drugs and as high as 100% with 
eight drugs. 
 Drug interactions become a higher risk when multiple medications are required to 
manage clinically complex individuals (Boyd, et al., 2005). As a result older adults are 
frequently at risk for medication- related issues (Foust, Naylor, Boling & Cappuzzo, 
2005) with all medication having the potential to harm as well as benefit (Tinetti, 
Bogardus, & Agostini, 2004).  And side effects, as a result of multiple medications, are 
often mistaken as a new onset of illness and treated with a new medication or simply 
accepted as a normal part of aging (Shrank, Polinski, & Avorn, 2007). 
Therapeutic Drug Class 
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 Increased risk for side effects can occur in older adults as a result of the 
significant differences in the way they metabolize medications (Hoskins, 2011).  
Physiological changes occur with advanced age to include decrease in renal function, 
decreased liver metabolism and alterations in the distribution of body water and fat that 
all impact on drug metabolism (Huisman-Baron et al., 2011). Slabaugh et al. (2010) 
reported older adults frequently used cardiovascular agents, antithrombotic agents and 
gastrointestinal agents. However there is a lack of clarity of how medication-related 
issues (therapeutic class of drug) relate to health-related quality in older adults (Classen, 
Mkanta, Walsh, & Mann, 2005).  The Beers Criteria developed explicit criteria to 
identify potentially inappropriate medication (PIM) use by older adults (Beers, 1991). 
The Beers Criteria published as original research in 1991, and revised in 2002 and 
2012, identified a number of drugs and drug classes that were potentially inappropriate 
for the elderly. These drugs were found to have a risk for adverse drug events (ADE) that 
outweighed the potential for a therapeutic gain (American Geriatric Society, 2012a; 
Beers,1997; Beers, Ouslander, Rollingher, Ruben, Brooks, & Beck,1991; Swagerty & 
Brickley, 2005).  The intention of the Beers Criteria was to reduce the use of potentially 
inappropriate medications (PIMs) in older adults and improve prescribing decisions by 
clinicians to reduce poor outcomes such as avoidable hospitalizations.  
Budnitz et al. (2011) examined emergency hospitalizations in adults 65 years and 
older and found that four medication classes either alone or in combination were 
associated in 67% (95% CI, 60.0 to 74.1) of hospitalizations: warfarin (33.3%), insulins 
(13.9%), oral anti-platelet agents (13.3%), and oral hypoglycemic agents (10.7%). 
Almost 50% of hospitalizations for adverse drug events (ADEs) involved adults 80 years 
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and older. Likewise, Boparai (2011) found the most common drug classes implicated in 
ADEs in older adults included cardiovascular drugs, antibiotics, diuretics, steroids, anti-
cholinergics, benzodiazepines and non-steriodal anti-inflammatory drugs. 
Hospitalizations for ADEs are predicted to increase as adults live longer, experience 
increased numbers of chronic conditions and consume more medications (Budnitz, 
Lovegrove, Shehab, & Richards, 2011).    
Similarly, Classen et al. (2005) compared medication drug classes and 
inappropriately prescribed medications to functional status and quality of life in frail 
home-based adults 65 years and older (n=1099) taking an average number of medications 
of 5.4 (SD ± 3.7). Cardiovascular medications were the most frequently (72%) used 
followed by gastrointestinal (41.3%), anti-inflammatory (41%) with cancer drugs having 
the lowest frequency (1.7%). Cardiovascular drugs were shown to have a positive 
association with motor performance (p=0.00) and cognition (p= 0.00). These findings 
suggest that increased age, increased number of chronic conditions and decreased health-
related quality of life are associated with greater number of medications. 
The literature demonstrates that while there have been efforts to improve the 
quality of medication use in older adults targeted towards specific issues (avoidance of 
inappropriate drugs, drug classes and doses)  have been important, they fail to include a 
more patient-centric focus related to health-related quality of life.  
Medication regimen complexity 
 Several studies have found complexity of a medication regimen is a significant 
driver of poor medication adherence (Choudhry et al., 2011; Mansur, Weiss, & 
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Beloosesky, 2012; Witticke, Seidling, Lohmann, Send, & Haefeli, 2013).  Complex 
medication regimens are more likely to be error prone which may impact patient safety 
and quality of life (Paquin et al., 2013).  In many situations the ability for an older adult 
to remain independent at home hinges on their capacity to manage a complex medication 
regimen, with non-adherence to regimens being a chief driver for nursing home 
placement (Marek & Antle, 2008).  Medication regimen characteristics such as the 
number of medications, dosage frequency, drug route and administration directions 
contribute to medication complexity resulting in lower adherence and increased risk for 
adverse drug events (Corsonello et al., 2009; Elliot, O'Callaghan, Paul, & George, 2013; 
Ingersoll & Cohen, 2008).   
 Clinical awareness regarding medication complexity can help identify patients at 
higher risk for adverse outcomes. George et al. (2004) developed a 65 item medication 
regimen complexity index tool as a way to quantify several components of medication 
regimen complexity. Weights were assigned to dosage forms, frequency of doses, and 
additional directions. The tool was validated by an expert panel that subjectively ranked 
six regimens to confirm the tool's criterion-related validity demonstrating strong 
agreement (Kendall's W = .8, p = 0.001). The value of the MRCI tool has gained recent 
interest as evidenced by the translation of the tool to other languages (Stange et al., 
2012), additional studies further validating the tool (Mansur, Weiss, & Beloosesky, 2012; 
Paquin et al., 2013) and other studies that have explored integrating the MRCI as part of 
clinical decision making ( Elliot,  2012; Elliot et al., 2013; Libby et al., 2013; McDonald 
et al., 2012; Rettig, Wood, & Hirsch, 2013). 
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 McDonald et al. (2012) further applied the MRCI by adapting it for use in 
electronic health records (EHR) in a home-care setting.  An automated process was 
developed to measure medication regimen complexity in a large population of post-acute 
discharged patients.  The original paper-based MRCI (George et al., 2004) was adapted 
using an electronic algorithm that automatically calculates the MRCI score for 
medications entered into the EHR by a home care nurse.  The number of total 
medications was highly associated with the total MRCI score and the greatest contributor 
to that score was dosing frequency (McDonald et al., 2012). This study provided the first 
comprehensive picture of medication regimen complexity in a large cohort of post-acute, 
community-dwelling patients characterized by multiple comorbidities and clinical 
complexity. The use of an automated MRCI tool may assist clinicians to identify patients 
with higher complexity with potential to improve medication management and overall 
outcomes for patients. 
Cardone et al. (2011) examined medication regimen complexity and health-
related quality of life in end-stage kidney disease patients (n=35) recently started on 
nocturnal home hemo-dialysis (NHHD) over a 24 month period. The SF-36 was used to 
measure health-related quality of life and the Medication Regimen Complexity Index 
(MRCI) was used to quantify regimen complexities. The MRCI scores increased 
significantly when patients were started on NHHD with a baseline mean score of 22.4 
(SD±10.2) and increased to a mean score of 28.3 (SD±11.6) at 24 months (p<0.05). The 
researchers concluded that increases in the MRCI scores were most likely due to 
dialysate requirements once NHHD was begun.  SF-36 scores improved significantly 
(p<0.05) from baseline through 24 months but MRCI scores were not significantly 
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related to the SF-36 score. Future studies are indicated to further explore the influence of 
different measures of medication regimen complexity and clinical outcomes such as 
health-related quality of life. 
 Wolf et al. (2011) explored whether patients inappropriately took multiple 
medications more frequently than prescribed due the regimen complexity. They assessed 
the accuracy and variability of how patients implemented a typical seven-drug regimen. 
The findings indicated that many patients took medications more frequently than 
indicated and those with inadequate literacy skills were a greatest risk for incorrect 
dosing. Furthermore, an increase in medication regimen complexity can at a minimum 
mean taking medication too often each day, causing adverse effects on overall health and 
intrusion in patients’ lives. 
Health-related quality of life and medication use 
 There is a need to better understand the potential intrusion that medication 
regimen complexity may play in an older adult's life.  Ebrahim (1995) stated generic 
health-related quality of life measurements have a role in the evaluation of medication 
therapy where unforeseen adverse effects of therapy might otherwise go unnoticed. 
Youssef & Wong (2002) suggest there may be value to better understand the subjective 
feelings of patients along with clinical assessment of health care interventions that 
include medication regimens. This should also be evaluated according to its effect on the 
health and quality of life of the individual. Henderson (2006) found the number of 
medications were associated with lower SF-36 Physical Component Scores (PCS) and the 
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number of medications (β= -.91, p= 0.045) to be predictive of lower health-related 
quality of life in older adults. 
 Holt et al. (2010) found that low health-related quality of life scores were 
associated with lower levels of anti-hypertensive medication adherence in adults over the 
age of 65 years old. Those with low physical and mental component summary scores on 
the Short Form (SF) 36 tool were 1.33 (95% CI 1.01, 1.74) and 2.26 (95% CI 1.74, 2.97) 
times more likely, respectively, to have lower medication adherence than those with 
higher PCS and MCS scores. 
 Older adults have a greater likelihood to experience multiple health issues that 
will require the use of multiple medications, resulting in a potential decline in health-
related quality of life (Cleary & Howell, 2007).  Community-based older adults reported 
an increase use of all medications with advancing age with the highest occurrence of drug 
use in females 65 years and older with 12% taking 10 or more medications (Kaufman, 
Kelly, Rosenberg, Anderson & Mitchell, 2002). Cleary & Howell (2007) examined 
health-related quality of life and prescription medication use in a study sample of adults 
aged 65 years and older (n=46) living in a rural region of the United States. The Short 
Form-36 version 2 (SF-36 v2) was used to measure health-related quality of life. 
Differences between subjects SF-36v2 physical component summary (PCS) and mental 
component (MCS) scores were compared based on gender and age and showed the mean 
PCS score for women was slightly better than men with a trend toward significance (p= 
0.06). This study supported the perception that health-related quality of life declines with 
age but did not find an association with prescription medication use. Of note, the average 
number of medication used (3.3) of the study subjects was lower than the national 
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average for older adults (4-5). The implications of these findings as they relate to the 
current study are: 1) the mean number of medications in the current study will be 
expected to be higher; 2) the subjects are from an urban area; 3) there is greater racial and 
ethnic diversity; and 4) the sample size will be larger (n=123). 
  Likewise, Henderson et al. (2006) examined the association of health-related 
quality of life and polypharmacy to determine the influence of demographic and clinical 
characteristics on this relationship among a group of older American Indians. An in-home 
interview and survey were conducted on a convenience sample (n = 63) of community-
dwelling American Indians.  The independent variables included total number of all 
prescription and nonprescription medications, age, education, annual income, health 
insurance, perceived health and medical history. The Medical Outcomes Short Form-36 
(SF-36) was used to measure health-related quality of life.  Increased use of medications 
were significantly associated with poorer self-reported health with the mean PCS score of 
36.5, (r=.30, p=.02). The study will build upon the literature in the following ways: (a) 
the subjects reside in an urban area; (b) larger sample size, and 3) majority are Hispanic 
older adults. 
While there have been efforts to improve the quality of medication use in older 
adults targeted towards specific issues to include avoidance of inappropriate drugs, 
specific drug classes and doses (Beers, 1991; Budnitz et al., 2011) have been important, 
they fail to include a more patient-centric focus related to health-related quality of life. 
Identifying outcome measures specific to health-related quality of life continues to pose 
challenges for nursing. Traditional measures, for example morbidity and mortality, do not 
provide adequate information concerning health-related quality of life. Yet clinicians may 
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remain unconvinced concerning the clinical significance of health-related quality of life, 
possibly because there is a paucity of research linking health-related quality of life to 
nursing-sensitive indicators (Sousa & Williamson, 2003).  
Summary  
 While the literature pertaining to health-related quality of life has emerged as a 
significant clinical indicator for older adults with chronic health problems, the evidence 
linking the use of multiple medications, therapeutic drug class, and medication regimen 
complexity, and health-related quality of life in older adults is lacking, and in particular 
in ethnically diverse older adults. Although the use of multiple medications has been 
widely explored in the literature, this literature review highlights the gaps regarding 
whether specific medication-related factors (number of active medications, number of 
therapeutic drug classes, medication regimen complexity) are related to health-related 
quality of life in older adults. The findings from this study explored whether key 
medication-related factors had a significant impact on health-related quality of life. 
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Chapter III 
The Method 
 The primary goal of this study was to examine the relationships of medication-
related factors (the number of active medications, the number of therapeutic drug classes, 
and medication regimen complexity) with health-related quality of life in older adults 
receiving  home and community-based services. The methodology used to test the 
research questions and hypotheses is presented in this chapter which is organized into six 
sections: a) overview of the primary study, b) study design, c) study sample and setting, 
d) data collection, e) instrumentation, and f) data analysis.   
Primary Study Overview 
 The data for this secondary analysis came from the baseline interviews and 
electronic health record abstractions of a large multi-site, longitudinal study investigating 
health-related quality of life in older adults recently transitioned to long term support 
services (LTSS). The primary study, Health Related Quality of Life: Elders in Long Term 
Care (R01-AG025524, PI, M. Naylor) was designed to examine the natural history of 
changes in health-related quality of life among older adults in three distinct settings to 
include nursing homes (NH), assisted living facilities (ALF) and home and community-
based services (H&CBS) and compare  patterns of change in each of the multiple 
domains of health-related quality of life across long-term  care settings by examining 
patterns among matched samples of older adults who remained in their setting for at least 
one year.  Eligibility criteria included adults age 60 years and older who were newly 
admitted (within 60 days) to one of the LTSS options; able to communicate verbally in 
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English or Spanish. Exclusion criteria included severe cognitive impairment (MMSE 
score of less than 12 at baseline), active psychiatric disorders, terminal illness, or 
admission to a LTC option for post-acute services with an expected plan for discharge 
from the LTC site.  The primary study site locations took place at two visiting nurse 
agencies (H&CBS) providing in-home LTSS (one was located in New York, NY); nine 
NHs; nine ALFs and two Program for All Inclusive Care of Elderly (PACE) programs. 
With the exception of the New York-based home and community-based agency, all study 
sites were located in the Philadelphia area.  Subject recruitment for the primary study was 
conducted at each study site based on eligibility criteria.  Designated site staff approached 
eligible potential subjects to describe the study. The names of subjects who were 
interested in learning more were then provided to study project staff who explained the 
study, administered the MMSE and sought informed consent.  Those subjects with 
MMSE scores of 12 or below were excluded and subjects with a score between13-22 
required additional consent from their legally authorized representative. The primary 
study commenced in 2007 (Hirschman, Abbott, Hanlon, Bettger, & Naylor. 2012) and 
data collection was completed in 2012.  
Design 
 This study was a secondary data analysis using baseline data collected by the 
primary study (R01AG025524-01A2, Principal Investigator, M. Naylor).  
Study Sample and Setting 
 As part of the multi-site primary study, Visiting Nurse Service of New York 
(VNSNY) CHOICE Health Plan was asked to recruit eligible older adults recently 
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admitted to their program to receive community-based LTSS. A review of the VNSNY 
CHOICE member census identified the Washington Heights and Inwood neighborhoods 
as having potentially eligible research subjects. Washington Heights and Inwood have a 
higher proportion (71%) of Hispanic residents than other areas in Manhattan (27%) and 
NYC overall (27%) (U.S Census, 2011).  According to Bergad (2008), beginning in the 
1980s, the upper Manhattan neighborhoods of Washington Heights and Inwood have 
become home to a large Hispanic population, making up 73% of the population by 2005 
with Dominicans representing the most prominent ethnic group. 
The sample for this study consisted of community-dwelling older adults (n =123) 
who were enrolled during 2007 and 2008 in the primary study (N = 470) previously 
described (R01-AG025524, PI, M. Naylor). Inclusion criteria for this study included 
individuals who were: 1) enrolled in the primary study, 2) aged 60 years and older, and 3) 
were recent recipients (within 60 days) of home and community-based services in New 
York City. Exclusion criteria for this study excluded any subject who did not reside in the 
community at time of enrollment. The initial baseline sample (n = 124) included all 
recruited subjects from the VNSNY site. One subject lived in an assisted living facility 
(ALF) and was therefore excluded. 
Human Subjects Protection 
 The policies and procedures of the Graduate Center of City University of New 
York and the Visiting Nurse Service of New York (which participated in the primary 
study and where this researcher was employed) were followed to seek and receive 
approval from their internal review boards (IRBs). The primary study had already been 
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approved by the Visiting Nurse Service of New York and the University of Pennsylvania 
IRBs. Certain medication-related factors were not collected as part of the baseline data by 
the primary study researchers. Therefore, additional medication-related factors including 
dosage form/route (e.g. tablet, injection) and additional directions (take with food, crush 
pill) required access to the subjects’ electronic health record for the additional data. 
VNSNY IRB approval was sought and obtained to re-identify subjects to facilitate access 
of the electronic health records to attain medication information. IRB approval was also 
received from Hunter College, CUNY in accordance with Graduate Center policies. 
Data Collection  
  Data for this secondary analysis were collected by the primary study as part of 
the baseline face to face interviews conducted at the time of enrollment and by retrieving 
data from electronic health records.  Following IRB approval, the VNSNY baseline data 
set was re-identified and the additional medication-related data were obtained from the 
subject’s electronic health record (EHR) by this researcher. Following retrieval of all 
medication data from the subject’s EHR data were de-identified and recorded on 
Microsoft excel spreadsheets using a password-protected computer with access limited to 
this researcher only.  To ensure all study data were examined at the same time point, the 
date of enrollment (see Appendix B) was used to retrieve the additional medication-
related data from the subject’s EHR.   
Instruments and Data Collection Procedures 
Demographic data measurement 
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 Baseline demographic data included age, gender, education, race, ethnicity, 
marital status and cognitive status. This data was obtained during the initial in-home 
interviews. These data were collected by the primary study on the demographic 
questionnaire (see Appendix G) as part of the Health Related Quality of Life Baseline 
Subject Interview developed and used in the primary study.   
Baseline HRQoL Chart Abstract Tool with Medication Data 
 The baseline HRQoL chart abstract tool (see Appendix C) collected the date of 
enrollment in the primary study. The tool was designed by the primary study to abstract 
data from the study subject's electronic health record to include their active medication 
list (see Appendix A). The baseline medication information initially collected by the 
primary study at baseline only included the name, dosage and frequency for each 
medication. The dosage form (tablet, injection) and additional directions (take with food, 
take at bedtime) were not included and were required to measure medication regimen 
complexity scores and were collected by this researcher. 
Cognitive Status 
 The Mini Mental State Exam (MMSE) was used in the primary study to measure 
cognitive status. The MMSE is a widely used global cognitive assessment tool that 
measures orientation to time and place, recalls ability, short-term memory and arithmetic 
ability in older adults (Folstein, Folstein, & McHugh, 1975). It consists of 20 questions, 
divided into two sections (see Appendix B). The first section requires verbal responses to 
orientation, memory, and attention questions, and the second section requires reading and 
writing and covers the ability to name, follow verbal and written commands, write a 
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sentence, and copy a polygon. The MMSE total score ranges from 0 to 30 and reflects the 
number of correct responses. Older adults scoring 24 or higher are considered to be 
cognitively intact, those with scores of 23-20 are mildly impaired and older adults with 
scores of 19-12 are moderately impaired (Pangman, Sloan, & Guse, 2000). For the 
purposes of regression analysis this variable was recoded to dichotomize cognitive status 
into cognitively intact (MMSE score ≥ 24) and cognitively impaired (MMSE ≤ 23). 
Medical Outcomes Study Short Form (SF-12v2)  
 Health-related quality of life was measured using the Medical Outcome Study 
(MOS) Short Form (SF-12v2) which is a multi-purpose generic measurement of health-
status (Ware, Kosinki, & Keller, 1996).  The MOS SF-12v2 (see Appendix D) is a 
psychometrically rigorous instrument frequently used by clinicians and researchers to 
measure and assess health- related quality of life  in a variety of patient populations 
(Brazier & Roberts, 2004; Borglin et al., 2004; Gandhi et al., 2001; Larson et al., 2008; 
Montazeri et al., 2011; Resnick & Nahm, 2001; Sousa & Williamson, 2003;).  The SF12- 
v2 contains 12 items, with a range of 3 to 5 response levels that measure eight aspects of 
general health to include physical functioning, role limitations due to physical health 
issues, bodily pain, general health, vitality, social functioning, role limitations due to 
emotional problems, and mental health (Ware et al., 1996).  The instrument uses a Likert 
scale of 1 to 3 for physical function items; 1 to 5 for bodily pain, social function and 
general health perception items; 1 to 5 for vitality and mental health; and a dichotomous 
scale (yes/no) for the presence of role function items (Ware, Kosinski, & Keller, 1996).   
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 The purpose of the MOS SF-12v2 in this study was to measure both physical and 
mental health-related quality of life using the physical component score (PCS-12) and 
mental component score (MCS-12) respectively. The sample (N=123) mean (M) and 
range results are noted for each item for both component scores (see Table 4.6). Higher 
scores indicate better self-perceptions of health.  
PCS-12 and MCS-12 scores can range between 0 to 100, with 0 indicating the 
lowest level of health and 100 indicating the highest level of health (Ware, Kosinski, & 
Keller, 1996).  Scoring of the SF-12 v2 PCS-12 and MCS-12 were created using norm-
based methods that standardized the scores to a mean of 50 and a standard deviation of 
10.  Norm-based scoring facilitates comparison of sample scores against the general 
population (Resnick & Nahm, 2001). The test-retest reliability for the PCS-12 was .89 
and the reliability coefficient of .76 was observed for MCS-12 in the general U.S. 
population (Ware et al., 1996, p.29). 
 Based on reliability estimates, the MOS SF-12v2 performed adequately in this 
study sample (N =123). Internal consistency for the SF 12 v.2 instrument for this sample 
was determined using the Cronbach's alpha coefficient. The results for this study (N 
=123) showed Cronbach's alpha coefficient for the physical component score approached 
0.70 (α for PCS-12 was .662) and the mental component score exceeded 0.70 (α for 
MCS-12 was .765).  
Active Medication Data Collection Procedure  
  Active medications, created as a continuous variable, were defined as the number 
of medications a subject was taking and included both prescription and over the counter 
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medications.  Data for active medications comprised a total of 1138 medications for the 
sample (N =123) with subjects taking an average of 9.3 medications (range 2-19) (see 
Table 4.2). Medication data was obtained from the medication list documented by a 
registered nurse in subject’s electronic health record (EHR). Medication data included the 
medication name, form or route (e.g. tablet, injection), frequency (e.g. once a day) and 
additional directions (e.g. take with food, crush tablet) and were routinely entered and 
documented in the subject’s EHR by home care nurses using tablet computers as part of 
usual care (personal communication, M. McDonald November 11, 2013).  In addition to 
prescription medications, over the counter medications were included in the EHR 
medication list as part of usual practice as they often play a vital role in a patient’s 
treatment plan and have potential to interact with prescription medications (McDonald et 
al., 2012). All medication data retrieved from the subject’s EHR were de-identified and 
recorded on Microsoft excel spreadsheets stored in a password-protected computer with 
access limited to this researcher only.  
Therapeutic Drug Class Measurement Tool 
 To enhance the precision of data about medication-related factors, this researcher 
developed a therapeutic drug class tool (see Appendix F) to measure the number of 
individual therapeutic drug classes represented in the subject’s medication regimen. Each 
medication that shared the same therapeutic class was matched according to one of the 12 
pre-determined therapeutic drug classifications in the established drug reference, Drug 
Facts and Comparisons 2013.  A 13th drug classification labeled "Other" was created to 
capture any medications that did not fit into any of the established drug classifications 
(e.g. Fish oil, Glucosamine). Each medication was assigned a therapeutic drug class (e.g. 
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cardiovascular, central nervous system, respiratory). Unique therapeutic drug classes 
were only counted once for each medication regimen. For example, a study subject taking 
two cardio-vascular medications and two gastrointestinal medications would have a total 
of two therapeutic drug classes (cardiovascular, gastrointestinal) counted in their 
regimen. The average number of therapeutic drug classes represented in the study sample 
was 4.89 with a range of 2-8 and was analyzed as a continuous variable (see Table 4.3). 
Medication Regimen Complexity Index 
 Medication regimen complexity was measured using the Medication Regimen 
Complexity Index (MRCI) (George et al., 2004). The MRCI is a valid and reliable 
instrument with strong inter-rater and test-retest reliabilities ≥0.9 (Elliot et al., 2013; 
George at el., 2004) The MRCI is a 65-item tool designed to quantify prescription 
medication in three components of medication regimen complexity. For the purpose of 
this study, over the counter medications were also included in addition to prescription 
medications. MRCI component "A" measures dosage form/route (e.g. tablets, eye drops, 
injections).  Each dosage form/route is counted only once within a regimen. For example, 
if a patient's regimen consists of four tablets that are taken orally, their MRCI component 
“A” sub-score would be one. The MRCI component "B" measures dosing frequency (e.g. 
once a day, every 12 hours, alternate days) for each medication. A weight is given to each 
medication frequency, with higher weights assigned to greater frequencies. For example, 
if a patient is taking six medications with a frequency of once a day for each medication, 
the MRCI component B subscore would be six. The third MRCI component “C” 
measures additional directions (e.g. crush pill, take with food, taper dose).  A weight is 
given for each instruction per medication. For example, if a patient is on a single 
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medication that needs to be crushed and taken with meals, the component C score for that 
medication is two. The Medication Regimen Complexity Index is a summary score of all 
three components.  There is no limitation to the number of medications or special 
directions that may be prescribed for a patient, and as a result the MRCI is an open index 
without upper limitations for ranging scores with higher scores indicating greater 
complexity (George et al., 2004). The range of total MRCI scores for this study sample 
ranged from 3 to 69, with a mean total score of 20.6 and was analyzed as a continuous 
variable (see Table 4.2). 
 The paper-based MRCI tool was adapted for electronic use in a study conducted 
in a large home and community-based organization (McDonald et al., 2012), the setting 
for the study sample used in this secondary analysis (and where this researcher was 
employed). McDonald et al. (2012) analyzed medication regimen complexity from 
electronic health records (EHR) of a large sample (N=89,645) of elderly home-care 
patients to develop and test the translation of the original MRCI components into an 
automated algorithm tool within the EHR. Scores for MRCI components A and B were 
calculated by directly mapping to electronic fields that contained this information. 
Certain regimens were abstracted and manually scored to ensure the programming was 
working correctly.  
Once all data were available to compute the MRCI score for each study subject, 
this researcher completed a paper-based MRCI tool and calculated component and total 
scores for each subject's medication regimen.  The MRCI results were then analyzed 
using SPSS Version 21.  Inter-rater reliability between the paper-based MRCI scores 
computed by this researcher and MRCI scores computed using the electronic algorithm 
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(EA) method previously described was tested. After receiving IRB approval, a researcher 
familiar with the development of the electronic MRCI algorithm scored 100% of the 
study sample (T. Peng, personal communication, July 13, 2013). Strong, positive 
statistically significant correlations were found for the total number of medications (r = 
.995, p ≤ .01) (see Table 3.1) and for all three MRCI components (dose forms, dosing 
frequencies, additional directions), demonstrating high degree of agreement between 
paper-based and electronic scores. The electronic algorithm (EA) MRCI scores were 
strongly and positively correlated with the researcher’s paper-based (PB) MRCI scores, 
specifically dosage form (MRCI A) (r = .954, p ≤ .01), dosing frequency (MRCI B) (r = 
.991, p ≤ .01), additional directions (MRCI C) (r = .895, p ≤ .01) and MRCI total scores 
(r = .984, p ≤ .01). 
Table 3.1 
Inter-rater Reliability for Medication Regimen Complexity Index (MRCI) tool: VNSNY 
Electronic Algorithm (EA) and Paper-based (PB) MRCI  
Variable Total Active 
Medications 
(EA) 
MRCI A 
(EA) 
MRCI B 
(EA) 
MRCI C 
(EA) 
MRCI 
Total (EA) 
Total Active 
Medications  
.995**     
MRCI A (PB)   .954**    
MRCI B (PB)   .991**   
MRCI C (PB)    .895**  
MRCI Total (PB)     .984** 
Note. **p ≤..001 
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Data Analysis 
 This study utilized a quantitative methodology for data collection and analysis. 
Prior to analyses, data were examined for accuracy and missing items. It was determined 
the health-related quality of life instrument, MOS SF-12 v2, had 4.8% (n=6) missing 
data. The missing data is just below the 5% missing data criterion recommended by 
Tabachnick and Fidell (2007). The total count of active medications, Therapeutic Drug 
Class and MRCI tool instruments had no missing data. To address the missing data, cases 
with missing data were excluded pair-wise which excludes the cases only if they are 
missing data required for the specific analysis (Tabachnick & Fidell, 2007).  
 The study covariates age, gender, race, ethnicity, education, marital status, and 
cognitive status were originally collected by the primary study. For regression analysis, 
certain variables were recoded as new dummy or dichotomized variables. Age was kept 
as a continuous variable.  Gender recoded as (0= female/ 1= male). Cognitive status was 
dichotomized (no impairment = 0 [MMSE >12 <23] / impaired =1 [MMSE ≥23]). 
Marital status was dichotomized (married = 0/ not married =1). Ethnicity was 
dichotomized and recoded (Hispanic = 1/ not Hispanic =0). 
Normality of variables was assessed using statistical and graphical methods to 
include histograms to identify outliers and the shape of distributions were examined for 
evidence of normal distribution. Descriptive statistics to include measures of central 
tendency were computed for study variables and for appropriate demographic data. The 
researcher examined the relationship between the number of active medications and the 
dependent variable (physical health-related quality of life) using Pearson’s product-
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moment correlation.  Partial correlations were computed to control co-variants (age, 
gender, education, race, ethnicity, marital status, and cognitive status). Full model 
multiple regressions were conducted for all covariates and physical and mental health-
related quality of life. The 0.5 alpha level was the criteria used for statistical significance 
in all analyses. Data were analyzed using the Statistical Packages for the Social Sciences 
(SPSS) Version 21.0 for Windows program to run statistical tests. 
Linear regression analyses was the analytical approach conducted to test all six 
research hypotheses to determine: (a) if the number of active medications predicted 
physical and mental health-related quality of life, (b) if the number of therapeutic drug 
classes predicted physical and mental health-related quality of life, and finally (c) if 
medication regimen complexity predicted physical and mental health-related quality of 
life.  
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Chapter IV 
The Results 
 This chapter presents the results of the statistical data analysis. The statistical 
findings of study are presented in three main sections: (a) descriptive statistics of sample 
characteristics and study variables, (b) main analysis to include linear regression models, 
for the six study hypotheses and (c) ancillary analysis. Presentation of the findings was 
summarized in narrative format and depicted in table format. 
Descriptive Statistics 
Sample Characteristics  
 The study sample was comprised of 123 older adults who recently began 
receiving home and community-based services provided by a home and community-
based agency. Overall subjects were 79 years old on average, the majority were female 
(75%), and Hispanic (68%). Fifty-nine percent only had an 8th grade education (see Table 
4.1). The majority of subjects (84%) had a mean MMSE score of 24.7 and almost half 
(42%) were widowed. Over one third (35%) of the sample were Black or African 
American. Of note, 37% (n =46) chose the "Other" category for race (see Appendix G).  
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Table 4.1  
Sample characteristics of older adults receiving H&CBS in Washington Heights and 
Inwood, NY, during 2007-2008 (N =123) 
Demographic 
Characteristics 
% n Mean (SD) Range (Min - Max) 
Age  123 79 yrs (7.7) 34 (63-97) 
  ≤ 75 years 36 44   
  76 - 83 years 31 38   
 ≥ 84 years 
 
33 41   
Gender     
  Female  
  Male 
 
75     
25 
92       
31 
  
Education   8 yrs (4.5) 21 (0 - 21) 
  ≤ 8th grade 59 72   
  9 - 12 years 28 35   
  > 12 years 
 
13 16   
Race      
  White 28 35   
  Black or AA 35 41   
  Native Hawaiian Pacific 1.6 2   
  Other 37 46   
Ethnicity     
   Hispanic 68 84 
 
  
Marital Status     
  Married 
  Widowed 
24 
42 
29 
52 
  
  Single 10 12   
  Divorced/Separated 24 29 
 
  
Cognitive Status   122 24.7 (2.94) 16 (14-30) 
  Impaired (MMSE >12 
<23) 
16 20   
  Not Impaired (MMSE 
≥23) 
84 102   
Note. H&CBS = Home and Community-Based Services. MMSE = Mini Mental State 
Exam. AA = African American 
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Medication-related Factors 
Active medications.  The average total number of active medications was 9.3 (SD 
3.6) with a range of 2-19 (see Table 4.2). 
Table 4.2   
Total Active Medications and Medication Regimen Complexity Characteristics of older 
adults receiving H&CBS in Washington Heights and Inwood, NY, during 2007-2008    
(N =123) 
Medication Variables  Mean (SD) Range  
Total Number of Active 
Medications* (unduplicated 
count) 
9.3 (3.6) 17 (2 - 19) 
 MRCI A (dosage forms) 4.8 (4.3) 21 (1 - 22) 
 MRCI B (frequency) 13.7 (6.7) 26 (2 - 38) 
 MRCI C (directions) 2.1 (2.2) 12 (0 - 12) 
 MRCI Total Score  20.6 (11.6) 66 (3 - 69) 
Note. * Includes prescription and over the counter medications. MRCI = Medication 
Regimen Complexity Index 
 
 Medication regimen complexity. MRCI total scores ranged from 3 to 69 (see 
Table 4.2) with a mean average of 20.6 (SD 11.6). The greatest contributor to the MRCI 
total score was dosing frequency (MRCI B) with a mean score of 13.7 (SD 6.7) with a 
range from 2 to 38, thus representing multiple medications and multiple dosing patterns.  
There was a strong correlation between the number of medications and the MRCI total 
score (r=.839, p≤.001) (see Table 4.7). 
There was wide variance of MRCI total scores found within regimens containing 
the same number of medications as noted in the two sample medication regimens (see 
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Tables 6 and 7). To illustrate this point, the MRCI total scores for 2 study subjects taking 
9 medications a day were compared to demonstrate the wide variance of medication 
regimen complexity. The MRCI total score computed in Regimen “A” was 25 and the 
MRCI score computed in Regimen “B” was 11 (see Figure 4.1).   
 
 
Figure 4.1.  Scatterplot of medication regimen complexity (MRCI) and total  
active medications  with example regimens for 2 subjects taking 9 medications. 
 
 
The first medication regimen example (see Table 4.3) was more complex with a 
MRCI total score of 25, which is approximately 25% higher than study sample average 
(20.6). The higher complexity was attributable to 1) multiple routes/forms (tablet and two 
forms of inhaled medications), 2) frequencies ranging from once daily up to every four 
hours as needed and 3) two additional directions (taking medication at a specific time 
(bedtime) and the using of multiple units (2 puffs) at one time).   
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Table 4.3 
Medication Regimen Example A: Older adult receiving H&CBS in Washington Heights 
and Inwood, NY, during 2007-2008 (n=1)     
Medication Regimen A:  9 medications with MRCI total score = 25 
Medication Form / Route  
(MRCI A) 
Frequency (MRCI B)  Directions (MRCI C) 
Singular Tablet / Oral Once a day Take a bedtime  
Motrin  Tablet / Oral Every 4 hours prn - 
HTCZ Tablet / Oral Once a day - 
Micardis Tablet / Oral Once a day - 
Amlodipine Tablet / Oral Once a day - 
Calcium  Tablet / Oral Once a day - 
Advair Diskus Inhalation / 
Aerolizer 
Twice a day Multiple units (2 
puffs) 
Spiriva Inhalation / 
Accuhaler 
Once a day - 
Ferrous Sulfate Tablet/ Oral Every 8 hours - 
Note. HCTZ = Hydrochlorothiazide. MRCI = Medication Regimen Complexity Index. 
PRN = take as needed 
 
The medication regimen in the second example (see Table 4.4) was less complex 
than was typical for patients taking nine medications. The MRCI score of 11 was 
approximately 49% lower than study sample average (20.6). The lower complexity in this 
example was attributable to using only one route/form (oral/tablet/capsule) with a once a 
day frequency for eight out of nine medications with no additional directions indicated. 
Table 4.4 
Medication Regimen Example B: Older adult receiving H&CBS in Washington Heights 
and Inwood, NY, during 2007-2008 (n=1) 
Medication Regimen B:  9 medications with MRCI total score = 11 
Medication Form/Route (MRCI A) Frequency (MRCI B)  Directions (MRCI C) 
Avandia Tablet / Oral Once a day - 
Vitamin C  Tablet / Oral Once a day - 
Omega 3  Capsule / Oral Once a day - 
Lipitor Tablet /  Oral Once a day - 
Glimepiride Tablet / Oral Twice a day - 
Prevacid  Capsule / Oral Once a day - 
Aspirin Tablet / Oral Once a day - 
Allopurinol Tablet / Oral Once a day - 
Lisinopril Tablet / Oral Once a day - 
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Therapeutic drug class. On average, the medication regimens of the subjects 
were comprised of five unique therapeutic drug classes with a range from two to eight 
classes.  The five most prevalent therapeutic drug classes (see Table 4.5) were 
cardiovascular agents (97%), central nervous system agents (94%), nutrients and 
nutritional agents (63%), gastrointestinal agents (60%), and endocrine and metabolic 
agents (59%).  Systemic anti-infective agents (6%) and biologic and immunologic agents 
(4%) had the lowest frequency of use. 
Table 4.5 
Characteristics of Therapeutic Drug Class (TDC) of older adults receiving H&CBS in 
Washington Heights and Inwood, NY, during 2007-2008 (N =123) 
Therapeutic Drug Class % N Mean (SD) Range  
Unique TDC per regimen  123 4.89 (1.5) 6 (2-8) 
TDC Frequencies     
  Cardiovascular 97  119   
  Central Nervous System 94  116   
  Nutrients & Nutritional  63  78   
  Gastrointestinal 60  74   
  Endocrine & Metabolic 59  73   
  Respiratory 35  43   
  Hematological 20  25   
  Renal & Genitourinary 16  20   
  Ophthalmic & Otic 13  16   
  Dermatological 11  13   
  Other  8  10   
  Systemic Anti-infective 6  7   
  Biologic & Immunologic 4 5   
Note. TDC = Therapeutic Drug Class 
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Health related quality of life 
 
 Health-related quality of life was measured using the Medical Outcomes Study 
Short Form (SF-12v2) (see Table 4.6).  The SF-12v2 produces two component scores 
(physical component score [PCS-12] and mental component score [MCS-12]) with higher 
scores indicating better health-related quality of life (Ware et al., 2002).  The results for 
the six items in the PCS-12 were in the lower range, measuring physical functioning (M= 
1.28) (range 1 -3), role limitations due to physical health problems to include limited stair 
climbing (M = 1.28) (range 1-3), accomplishing less (M = 2.8) (range 1-5), limited work 
or activities (M = 2.77) (range 1-5), bodily pain (M = 3.18) (range 1-5) and general health 
(M =(range 1-5). Physical health-related quality of life for the study sample indicated 
lower than average physical health ratings. The mean PCS-12 score of 31.2 (SD 7.66) for 
the sample which is well below the average norm-based PCS-12 score of 50 (Resnick & 
Nahm, 2001).  
The results for the six items in the MCS-12 were higher range measuring vitality 
(energy) (M = 2.58) (range 1-5),  social functioning (M = 3.24) (range 1–5), role emotion 
(accomplished less) (M =3.46) (range 1-5), role emotion (not careful) (M =3.76) (range 
1-5), mental health (felt calm & peaceful) (M = 3.43) (range 1-5), mental health 
(downhearted and depressed) (M = 3.24) (range 1-5).  The average MCS-12 was higher 
than the PCS-12 with a mean score of 47.3 (SD 10.5) which is closer to the norm-based 
average of 50 (Resnick & Nahm, 2001). The study subjects on average had higher mental 
component scores when compared to their physical component scores (PCS-12).  
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Table 4.6 
Characteristics of Health related Quality of Life of older adults receiving H&CBS in 
Washington Heights and Inwood, NY, during 2007-2008 (N =117) 
MOS SF-12v2 Mean (SD) Range (Min-Max) 
Physical HRQoL    
(PCS-12) 
31.2 (7.66) 37 (14-51) 
Mental HRQoL 
(MCS-12) 
47.3 (10.5) 56 (14-70) 
Note. MOS SF-12v2 = Medical Outcomes Study Short Form (SF-12 v2). PCS-12 = 
Physical Component Score. MCS-12 = Mental Component Score. 
 
Main Analysis 
 Main analysis examined the relationships between the dependent variables, 
physical and mental health-related quality of life, and the independent variables:  number 
of active medications, number of therapeutic drug classes, and medication regimen 
complexity. The correlation matrix for the study variable is reported on Table 10.  
Cohen’s (1988) guidelines for evaluating correlational results for the behavioral sciences 
were used to interpret the strength of the correlations. The study sample size (N = 123) 
met the required number of minimum cases recommended when using multiple 
regression. Preliminary analyses were conducted to determine there were no violation of 
assumptions of normality, linearity, outliers, multicollinearity and homoscedasticity 
(Tabachnick & Fidell, 2007). The Normal Probability Plots (P-P) suggested no deviation 
from normality.  The scatterplot of the standardized residuals supported homoscedasticity 
and indicated no visible patterns or outliers. Collinearity diagnostics for the independent 
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variable (VIF =1.0, Tolerance = 1.0) did not violate the assumption of multicollinearity. 
The maximum value for Cook’s Distance was .28 suggesting no major issues of undue 
influence on the results. Scores larger than 1.00 are most likely due to outliers 
(Tabachnick & Fidell, 2007).   
Table 4.7 
Correlation Matrix of Associations Among Main Study Variables (N =123) 
Variable Physical 
HRQoL    
(PCS-12) 
Mental 
HRQoL 
(MCS-12) 
Total Active 
Medications 
Therapeutic 
Drug Class 
MRCI 
Total Score 
Physical 
HRQoL    
(PCS-12) 
 -.117 -.185* -.046 -.081 
Mental 
HRQoL 
(MCS-12) 
  -.101 -.157 -.076 
Total Active  
Medications 
   .720** .839** 
Therapeutic 
Drug Class 
    .651** 
Note.**p ≤.001, one tailed. *p ≤ .05.  HRQoL = Health-related quality of life. PCS-12 = 
Physical Component Score. MCS-12 = Mental Component Score. MRCI = Medication 
Regimen Complexity Score. 
Testing the Research Hypotheses 
Research question 1. Is there an association between the number of active medications 
and health-related quality of life in older adults receiving community-based LTSS before 
and after controlling for age, gender, education, race, ethnicity, marital and cognitive 
status? 
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 H1a: The number of active medications will be associated with physical health-
related quality of life in of older adults receiving community-based LTSS. 
 A Pearson product-moment correlation was calculated to explore the relationship 
between the number of active medications (M = 9.3) and physical health-related quality 
of life (measured by PCS-12) (M = 31.2). Before controlling for age, gender, education, 
race, ethnicity, marital and cognitive status, this analysis was found r = -.185, indicating a 
small negative relationship between the total number of active medications and physical 
health-related quality of life.   
 Partial correlation was used to explore if the relationship between physical health-
related quality of life and the total number of active medications while controlling for 
age, gender, education, race, ethnicity, marital and cognitive status. There was a small, 
negative partial correlation between physical health-related quality of life and the total 
number of active medications controlling for age, r = -.194, p <.05,  education , r = -.185, 
p <.05, race r = -.184, p <.05, ethnicity, r = -.185, p <.05, marital status, r = -.188,  p 
<..05, and cognitive status, r = -.193, p <.05. An inspection of the zero order correlation 
(r = -.185) suggested that controlling for age, education, race, ethnicity, marital and 
cognitive status had very little effect on the strength of the relationship between the two 
variables. There was a small decrease in the strength of the correlation (from -.185 to -
.171) when controlling for gender, r = -.171, p =.06. 
  A simple linear regression was performed (see Table 4.8).  It was found that the 
total number of medications significantly predicted physical health-related quality of life 
(β = -.185, p = .046). A multiple regression was than conducted adjusting for age, gender, 
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education, race, ethnicity, marital status and cognitive status. After adjusting for the 
covariates, the predictive power of total number of active medications on physical health-
related quality of life was reduced (β = -.186, p = .062) (see Table 4.8). These results 
indicated that for every unit increase in medication, physical health-related quality of life 
decreases by .5, interpreted to mean that people taking more medications will have a 
decrease in physical health-related quality of life. 
H1b: The number of active medications will be associated with mental health-
related quality of life in of older adults receiving community-based LTSS. 
 A Pearson product-moment correlation was calculated to explore the relationship 
between the number of active medications (M = 9.3) and mental health-related quality of 
life (MCS-12) (M = 47.3). This analysis found that there was a non-significant 
correlation, r = -.101, p >.05, between the number of active medications and mental 
health-related quality of life. 
 A simple linear regression was performed before adjusting for age, gender, 
education, race, ethnicity, marital status and cognitive status (see Table 4.9).  The total 
number of active medications did not predict mental health-related quality of life (β = -
.101, p = .279). A multiple regression was then conducted adjusting for age, gender, 
education, race, ethnicity, marital status and cognitive status. After adjusting for the 
covariates, the total number of active medications did not predict mental health-related 
quality of life (β = -.041, p = .676). 
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Research Question 2 
Research question 2.  Is there an association between the number of therapeutic drug 
class and health-related quality of life of older adults receiving community-based LTSS 
before and after controlling for age, gender, education, race, ethnicity, marital and 
cognitive status? 
 H2a: The number of therapeutic drug classes will be associated with  
physical health-related quality of life in older adults receiving community-based LTSS. 
  A Pearson product-moment correlation was calculated to explore the relationship 
between the number of therapeutic drug classes (M = 4.9) and physical health-related 
quality of life (PCS-12) (M = 31.2). This analysis found that there was a non-significant 
correlation, r = -.046, p >.05, between the number of therapeutic drug classes and 
physical health-related quality of life.  
 A simple linear regression was performed before adjusting for age, gender, 
education, race, ethnicity, marital status and cognitive status (see Table 4.8) The number 
of therapeutic drug classes did not predict physical health-related quality of life (β = -
.046, p =.623). A multiple regression was then conducted adjusting for age, gender, 
education, race, ethnicity, marital status and cognitive status. The results of the regression 
indicated that the number of therapeutic drug classes did not predict physical health-
related quality of life (β = -.044, p = .651) (see Table 4.8). 
 H2b: The number of therapeutic drug class will be associated with mental health-
related quality of life in older adults receiving community-based LTSS. 
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 A Pearson product-moment correlation was calculated to explore the relationship 
between the number of therapeutic drug class (M = 4.9) and mental health-related quality 
of life (MCS-12) (M = 31.2). Before controlling for gender, age, education, marital status, 
ethnicity, race, and cognitive function, this analysis found that there was a non-significant 
correlation, r = -.091, p >.05, between the number of therapeutic drug classes and mental 
health-related quality of life.  
 A simple linear regression was performed before adjusting for age, gender, 
education, race, ethnicity, marital status and cognitive status (see Table 4.9).  The total 
number of therapeutic drug classes did not predict mental health-related quality of life (β 
= -.157, p = .091). A multiple regression was then conducted adjusting for age, gender, 
education, race, ethnicity, marital status and cognitive status. After adjusting for the 
covariates, the number of therapeutic drug classes did not predict mental health-related 
quality of life (β = -.114, p = .230) (see Table 4.9). 
Research Question 3 
 Research question 3. Is there an association between medication regimen 
complexity and health-related quality of life in older adults receiving community-based 
LTSS before and after controlling for gender, age, number of years of education, marital 
status, ethnicity, race, and cognitive status? 
  H3a: Medication regimen complexity will be associated with physical health-
related quality of life in older adults receiving community-based LTSS. 
 A Pearson product-moment correlation was calculated to explore the relationship 
between medication regimen complexity (M = 20.6) and physical health-related quality of 
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life (PCS-12) (M = 31.2). This analysis found that there was a non-significant correlation, 
r = -.081, p >.05, between the medication regimen complexity and physical health-related 
quality of life. 
 A simple linear regression was performed before adjusting for age, gender, 
education, race, ethnicity, marital status and cognitive status (see Table 4.8) Medication 
regimen complexity did not predict physical health-related quality of life     (β = -.081, p 
=.387). A multiple regression was then conducted adjusting for age, gender, education, 
race, ethnicity, marital status and cognitive status. After adjusting for the covariates, 
medication regimen complexity did not predict physical health-related quality of life (β = 
-.074, p = .458) (see Table 4.8). 
H3b: Medication regimen complexity will be associated with mental health-
related quality of life in older adults receiving community-based LTSS. 
 A Pearson product-moment correlation was calculated to explore the relationship 
between medication regimen complexity (M = 20.6) and mental health-related quality of 
life (MCS-12) (M = 47.3). This analysis found that there was a non-significant 
correlation, r = -.076, p >.05, between the medication regimen complexity and mental 
health-related quality of life. 
 A simple linear regression was performed before adjusting for age, gender, 
education, race, ethnicity, marital status and cognitive status. Medication regimen 
complexity did not predict mental health-related quality of life (β = -.076, p = .416). A 
multiple regression was then conducted adjusting for age, gender, education, race, 
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ethnicity, marital status and cognitive status. Medication regimen complexity did not 
predict mental health-related quality of life (β = -.008, p = .938) (see Table 4.9). 
Ancillary Analysis 
Medication-related variables and Health-related quality of life 
 To further explore the relationships among the independent variables (total 
number of active medications, number of therapeutic drug classes, and medication 
regimen complexity) the study covariates (age, gender, education, race, ethnicity, marital 
status and cognitive status) and the dependent variables (physical and mental health-
related quality of life) multiple regression, using a fully adjusted model, was conducted 
for physical (see Table 4.8) and mental health-related quality of life (see Table 4.9). 
 Physical Health-related quality of life.  A summary of the regression 
coefficients is presented in Table 11 and indicated that the number of total active 
medications remained significant in predicting physical health-related quality of life (β = 
-.497, p = .012), while the number of therapeutic drug classes (β = .156, p = .266) and 
medication regimen complexity (β = .234, p = .189) were not associated with physical 
health-related quality of life after controlling for age, gender, education, race, ethnicity, 
marital status and cognitive status. 
 Mental health-related quality of life.  Regression results (see Table 12) indicate 
the overall model was not significant, F(10,105) = 1.182, p = .311. A summary of the 
regression coefficients is presented in Table 12 and indicates the total number of active 
medications (β = .001, p = .996), the number of therapeutic drug classes (β = -.190, p = 
.172) and medication regimen complexity (β = .118, p = .504) were not associated with 
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mental health-related quality of life after adjusting for age, gender, education, race, 
ethnicity, marital status and cognitive status.   
Study Variables and the Demographic Data 
 As a final step, attention was focused on the role of the demographic data in 
relation to the study variables. Differences in the means were examined for demographic 
characteristics and the study variables.  The demographic factors included age, gender, 
education, race, ethnicity, martial and cognitive status. Both significant and non-
significant results were reported for selected variables. 
 Health-related quality of life and age. A one-way between-groups analysis of 
variance (ANOVA) was conducted to explore the impact of age on health-related quality 
of life based on the mean scores for physical (PCS-12) and mental (MCS-12) (see Table 
9). Subjects were divided into three approximately equal groups according to their age 
(Group 1: ≤75 yrs, n = 41, Group 2: 76-83 yrs, n = 37, Group 3: ≥84 yrs,   n = 39). Equal 
variances, as noted by non-significant (p > .05) Levene’s test of Homogeneity were 
present for both PCS-12 and MCS-12 analysis. There was no statistically significant 
differences in the PCS-12 mean scores across the three age groups: F(2, 114) = .074, p > 
.05.  In addition, there was no statistically significant difference in the mean MCS-12 
scores:  F(2, 114) = 2.81, p > .05. 
 Health-related quality of life and gender. An independent-samples t-test was 
conducted to compare health-related quality of life physical (PCS-12) and mental (MCS-
12) scores for females and males in the study subjects. There was no significant 
difference in PCS-12 scores for females (M= 30.8, S.D = 7.6) and males (M= 32.6, S.D = 
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7.6; t (115) = -1.1, p =.27, two-tailed). The magnitude of the differences in the means 
(mean difference = -1.78, 95% CI:-4.99 to 1.42) was small (eta squared = .01) according 
to Cohen's (1988) guidelines.  There was no significant difference in the MCS-12 scores 
for females (M =46.9, S.D = 10.5) and males (M = 48.3, S.D = 10.54; t(115) = -.608, p = 
.54, two-tailed). The magnitude of the differences in the means (mean difference = -1.3, 
95% CI: -5.7 to 3.07) was very small (eta squared = .003). 
 Health-related quality of life and ethnicity. An independent-samples t-test was 
conducted to compare health-related quality of life physical (PCS-12) and mental (MCS-
12) scores for Hispanic and non-Hispanic study subjects. There was no significant 
difference in PCS-12 scores for Hispanics (M= 31.2, S.D = 7.1) and non-Hispanics (M= 
31.2, S.D = 9.1; t (115) =   -.019, p =.98, two-tailed). The magnitude of the differences in 
the means (mean difference = -.021, 95% CI:-3.13 to 3.07) was very small (eta squared = 
.001) according to Cohen's (1988) guidelines.  There was no significant difference in 
MCS-12 scores for Hispanics (M =47.6, S.D = 10.4) and non-Hispanics (M = 46.6, S.D = 
10.9; t(115) = .468, p = .64, two-tailed). The magnitude of the differences in the means 
(mean difference = 1.0, 95% CI: -3.2 to 5.2) was very small (eta squared = .003). 
Medication-Related Variables and Age 
 Medication Regimen Complexity Index and Age. An ANOVA was conducted 
to explore the impact of age on medication regimen complexity as measured by the 
MRCI tool. Subjects were divided into three groups according to age (Group 1: ≤75 yrs, 
n = 41, Group 2: 76-83 yrs, n = 37, Group 3: ≥84 yrs,  n = 39). The results revealed 
statistically significant mean differences in medication complexity based on age, F (2, 
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120) = 3.419, p = .036. All groups were close to but not equal in numbers and ranged 
from n = 37 (76 – 83 yrs) to n = 41 (≤ 75 years). When cell size are unequal, at test of 
homoegeneity should be confirmed (Polit & Beck, 2012).  Equal variances, as noted by 
non-significant (p > .068) Levene’s test of Homogeneity of Variances were present. The 
difference in the mean scores approached a moderate effect based on Cohen’s (1988) 
classification terms of effect size. The effect size, calculated using eta squared, was .05. 
Post hoc comparisons (Tukey) indicated that the mean score for Group 1 (M = 22.9, S.D 
10.5) was statistically significantly different (p <.05) from Group 3 (M =16.9, S.D = 8.2). 
Group 2 (M =22.2, S.D =14.8) did not differ significantly from either Group 1 or 3.  
Summary of Results 
 In this chapter, a demographic analysis of the sample characteristics and 
descriptive statistics for all independent and dependent study variables were discussed. 
Main analysis of the research hypotheses revealed that the total number of medications 
was predictive of physical health-related quality of life. This finding indicates that for 
every unit increase in medication, physical health-related quality of life decreases by .5, 
interpreted to mean that people taking more medications will have a decrease in physical 
health-related quality of life. Simple regression analyses revealed that therapeutic drug 
class and medication regimen complexity were not associated with physical health-
related quality of life.  In addition, multiple regression analysis revealed that the total 
number of active medications, therapeutic drug class and medication complexity were not 
associated with mental health related quality of life.  
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 Analysis of variance (ANOVA) revealed that mean medication regimen 
complexity scores were significantly different based on age. Younger adults (aged 75 
years or younger) had higher mean medication complexity scores on the MRCI than 
adults aged 84 years and older. 
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Table 4.8 Regression of Total Number of Active Medications, Number of 
Therapeutic Drug Classes, and Medication Regimen Complexity Index on Physical 
Health-Related Quality of Life in older adults receiving H&CBS in Washington Heights 
and Inwood, NY, 2007-2008. 
 Unadjusted  Adjusted*  
 ß Coefficient          P value    ß Coefficient        P value  
Total Active Medications  
Total Active Meds  -.185 .046  -.186 .062  
Age, years    -.041 .694  
Gender, Female    .086 .399  
Education, years    .087 .436  
Race, White    .031 .756  
Ethnicity, Hispanic    -.047 .665  
Marital Status    .085 .417  
Cognitive Status    .015 .890  
Number of Therapeutic Drug Class (TDC) 
TDC -.046 .623  -.044 .651  
Age, years    -.008 .937  
Gender, Female    .115 .262  
Education, years    .097 .389  
Race, White    .458 .648  
Ethnicity, Hispanic    -.055 .622  
Marital Status    .081 .447  
Cognitive Status    -.001 .992  
Medication Regimen Complexity Index (MRCI) 
MRCI  -.081 .387  -.074 .458  
Age, years    -.020 .851  
Gender, Female    .110 .283  
Education, years    .092 .416  
Race, White    .041 .678  
Ethnicity, Hispanic    -.060 .585  
Marital Status    .085 .424  
Cognitive Status    -.002 .983  
Total Active Medications, Total Number of TDC, MRCI 
Total Active Meds    -.497 .012  
TDC    .156 .266  
MRCI     .234 .189  
Age, years    -.021 .841  
Gender, Female    .069 .497  
Education, years    .083 .756  
Race, White    .020 .840  
Ethnicity, Hispanic    -.046 .673  
Marital Status    .101 .335  
Cognitive Status    .032 .764  
Note. * Adjusted for all variables listed. TDC = Therapeutic Drug Class. MRCI = 
Medication Regimen Complexity Index
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Table 4.9  Regression of Total Number of Active Medications, Number of 
Therapeutic Drug Class, and Medication Regimen Complexity Index on Mental Health-
Related Quality of Life in older adults receiving H&CBS in Washington Heights and 
Inwood, NY, 2007-2008. 
 Unadjusted  Adjusted*  
 ß Coefficient    P value    ß Coefficient        P value  
Total Number of Active Medications  
Total Active Meds  -.101 .279  -.041 .676  
Age, years    .264 .012  
Gender, Female    .058 .562  
Education, years    .119 .279  
Race, White    .048 .621  
Ethnicity, Hispanic    -.152 .159  
Marital Status    .068 .507  
Cognitive Status    .041 .701  
Number of Therapeutic Drug Classes (TDC) 
TDC -.157 .091  -.114 .230  
Age, years    .253 .014  
Gender, Female    .057 .563  
Education, years    .122 .261  
Race, White    .051 .598  
Ethnicity, Hispanic    -.140 .194  
Marital Status    .057 .577  
Cognitive Status    .043 .680  
Medication Regimen Complexity (MRCI)  
MRCI  -.076 .416  -.008 .938  
Age, years    .271 .011  
Gender, Female    .064 .518  
Education, years    .121 .272  
Race, White    .051 .601  
Ethnicity, Hispanic    -.155 .151  
Marital Status    .068 .507  
Cognitive Status    .037 .727  
Total Active Medications, Number of TDC, MRCI 
Total Active Meds    .001 .996  
TDC    -.190 .172  
MRCI     .118 .504  
Age, years    .271 .011  
Gender, Female    .064 .522  
Education, years    .131 .233  
Race, White    .058 .555  
Ethnicity, Hispanic    -.131 .231  
Marital Status    .051 .624  
Cognitive Status    .045 .670  
Note. *Adjusted for all variables listed. TDC = Therapeutic Drug Class. MRCI = 
Medication Regimen Complexity Index. 
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Chapter V 
Discussion 
 This chapter discussed the results of this study based on: (a) the six research 
hypotheses within the context of findings and related literature, (b) integration of the 
theoretical rationale, (c) study sample characteristics, (d) ancillary findings, and (e) a 
review of the strengths and limitations of the research.  
Overview of the Study 
 Medication regimens for each subject were examined in detail. Regression 
analysis, controlling for age, gender, education, race, ethnicity, marital status and 
cognitive status, determined that the number of active medications was a key predictor of 
physical health-related quality of life but was not associated with mental health-related 
quality of life. Therapeutic drug class and medication regimen complexity were not 
associated with either physical or mental health-related quality of life.  This was the first 
study that explored these medication-related independent variables together in the context 
of health-related quality of life within a community-dwelling, minority older adult 
population receiving long-term services and supports. 
First Hypotheses (H1a and H1b) 
 This study hypothesized that the number of active medications would be 
associated with physical and mental health-related quality of life before and after 
controlling for age, gender, education, race, ethnicity, marital status and cognitive status. 
The data from the study determined that the number of active medications predicted 
physical health-related quality of life before controlling for the covariates and remained 
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significant in a fully adjusted model. For every unit increase in the number of active 
medications, physical health-related quality of life decreases by 0.5. In other words, older 
adults who take more medications have a decrease in physical health-related quality of 
life. The number of active medications was not associated with mental health-related 
quality of life before or after controlling for covariates.  
 The National Center for Health Statistics (NCHS) (2010) reported trends in 
prescription drug use continue to increase among older adults (aged 60 and over) with 
88% using at least one prescription drug per day. More than 76% use two or more 
prescription drugs and 37% use five or more. 17% of men and 19% of women use at least 
ten medications on a regular basis (Slone Survey, 2006). Overall women use more 
prescription drugs than men and non-Hispanic whites have the highest prescription drug 
use when compared the Mexican-American population who have the lowest utilization 
(NCHS, 2010).  Comparatively, the data from this study indicated the average number of 
medications was 9.3 with a range from 2 to 19. Females used an average of 9.6 
medications and males used an average of 8.2. Hispanics used an average of 9.2 
medications and non-Hispanics used an average of 9.3. The results indicate a higher 
degree of medication use when compared to the national data for age, gender and 
ethnicity. 
 The use of multiple medications, also known as polypharmacy, in older adults has 
been widely recognized in several studies to increase drug related problems affecting 
patient safety (Elliot et al., 2013; Institute of Medicine [IOM], 2006; Liu, Manias, & 
Gerdtz, 2010), quality of care (American Geriatrics Society [AGS], 2012a; AGS, 2012b; 
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Roth et al., 2009), decline in functional status, avoidable hospitalizations and increased 
health-care costs (Budnitz et al., 2011; Slabaugh et al., 2010; Tinetti et al., 2014).   
Yet gaps exist as few studies have explored the relationships of multiple medication use 
and health-related quality of life in community-dwelling older adults. There were no 
studies found that examined medication regimens of community-dwelling minority older 
adults to the level of detail conducted in this study. The findings of the current study 
support others showing that the number of medications used in older adults was a 
significant predictor of physical health-related quality of life. 
 Francic & Jiang (2006) investigated the relationship between potentially 
inappropriate medication use and two generic health-related quality of life measures, the 
SF-12 and EuroQol’s EQ-5D. Using a longitudinal retrospective cohort design, the 
researchers conducted secondary analysis of adults 65 years of age and older who were 
part of the national 1996 Medical Expenditure Panel Survey (MEPS). The study found 
that the number of drugs prescribed was a significant predictor of health-related quality 
of life for PCS-12 (r= -.237) and EQ-5D VAS (r = -.361) which indicated that a higher 
number of prescribed medications predicted poor physical health-related quality of life.  
 Additionally, a large study (N = 1099) using secondary analysis from the 
Consumer Assessment Study included frail community-based older adults with an age 
range from 60 to 106 years of age, 73% female and 80% White (Classen, Mann, Wu, & 
Tomita, 2004). The study examined the relationship between the number of medications 
and functional status, and health-related quality of life. The average number of 
medications was 5.4 (S.D 3.8) from 13 different drug classes. Two global self-rated 
quality of life questions were asked, but were lacking validity or reliability measurement 
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data. The findings indicate that increased age, increase number of chronic diseases and 
decrease in health were all associated with higher numbers of medications.  The lack of 
psychometric properties for the health and quality of life questions were of concern in 
this study. The average number of medications was lower (5.4) compared to the current 
study (9.3).   
 In two smaller cross-sectional studies, findings indicated significant associations 
between polypharmacy and physical health-related quality of life.  Sorensen et al. (2005) 
reported poor patient outcomes to include decrease in physical health-related quality of 
life in community-based study of older adults (N = 204) living in Australia. The sample 
average age was 72.4 years and 61% female. Patients self-reported taking on average of 
9.9 medications during office visits. When home visits were conducted by clinicians, the 
average number of medications found in the home increased to14.7.  Medication-related 
risk factors identified included the total number of medications, having no established 
routine for medication administration, recent reports of adverse drug events (ADE), 
therapeutic duplications, hoarding medications, and lack of knowledge regarding brand 
name versus generic. The medication-related factors related to decrease in physical 
health-related quality of life (measured by the SF-36 PCS) and severity of illness 
included an increased in number of medications (p<.001), recent ADEs and therapeutic 
duplications. 
 Likewise, Henderson et al. (2006) examined the association of polypharmacy and 
health-related quality of life in a small sample (N = 63) of community-dwelling American 
Indians aged 50 years and older. The average number of medications was 9.8 for males 
and 10 for females with a range from 4 to 19. Health related quality of life was measured 
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by the MOS SF-36 PCS and MCS scores. The PCS score (r= -.91, p=.045) was 
associated with the degree of polypharmacy before and after controlling for age, gender 
and chronic disease. The current study is similar in the average number and range of 
medications, although the demographic characteristics differ in age and ethnicity. 
 Cleary & Howell (2007) examined prescription drug use and health-related 
quality of life in rural adults aged 65 years and older (N =43).  The sample was 98% 
White with an average age of 78 years. The mean number of medications was 3.6 Health 
related quality of life was measured by the SF-36 PCS and MCS scores. The study found 
no significant association between PCS and MCS and the number of medications. 
 The existing research suggests that older adults who take more medication have a 
decrease in physical health-related quality of life. Research specifically examining the 
relationships between medication use and health-related quality of life among 
predominately Hispanic older adults has not been widely studied. The findings of this 
study support current evidence and expand the demographics with the inclusion of an 
ethnic population (68% Hispanic). This study strengthens the evidence regarding the 
potential negative impact of multiple medication use can have in older adults. 
Second Hypotheses (H2a and H2b) 
 It was hypothesized that the number of therapeutic drug classes would be 
associated with physical and mental health-related quality of life before and after 
controlling for age, gender, education, race, ethnicity, marital status and cognitive status. 
The data suggested that the number of therapeutic drug classes was not associated with 
either physical or mental health-related quality of life before and after controlling for the 
covariates. 
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 The majority of literature investigating therapeutic drug classes is related to the 
risk of adverse drug events as a result of specific drug classes. Several studies support the 
contribution of specific drug classes to increase risk of falls (Tinetti et al., 2014), 
confusion, and adverse drug events (AGS, 2012a; Choudry et al., 2011). Many 
preventable adverse drug events are associated with cardiovascular drugs, non-opioid 
analgesics, hypoglycemic agents, anticoagulants, and opioids (Bopari & Korc-Grodzicki, 
2011; Gurwitz et al., 2003).  Budnitz et al. (2011) found adults aged 65 years and older 
were admitted for emergency hospitalizations as result of four common medications and 
medication classes taken either alone or combination: warfarin (33.3%), insulins (13.9%) 
oral anti-platelet agents (13.3%) and oral hypoglycemic agents (10.7%).  Hospitalizations 
resulting from hematologic agents were for acute hemorrhages (71.3%) and almost all 
hospitalizations due endocrine agents were a result of hypoglycemia (94.6%). 
  Some studies have explored the relationship of specific drugs or drug classes and 
health related quality of life in community-dwelling older adults aged 65 years and older 
including:  treatment of high cholesterol with cholesterol lowering drugs (Carlsson, 
Papcke-Benson, Carnes, McBride, & Stein, 2002),  and older and younger adults with 
insulin-treated diabetes (Trief, Wade, Pine, & Weinstock, 2003).  Carlsson et al. (2002) 
used a double-blind RCT design in a small sample (N =41) and measured the Global 
Health Perception Question. Findings determined health-related quality of life scores did 
not change after 12 months of therapy with cholesterol lower agents. Trief et al. (2003) 
examined health-related quality of life measured by the SF-36 PCS and MCS scores and 
found when compared to a younger cohort, older adults with insulin-treated diabetes 
encountered more decline in physical health-related quality of life, but revealed higher 
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mental health-related quality of life with better coping and social supports that may 
account for reduced levels of distress related to diabetes. 
 Holt et al. (2010) examined health-related quality of life and antihypertensive 
medication adherence in a large cohort (N = 2,180) of community-dwelling older adults 
aged 65 and older.  The average age of the participants was aged 75 years, 70% were 
white, 58.5% were women and 14% had low medication adherence. Health-related 
quality of life was measured using the MOS SF-36 tool. Lower physical and mental 
health-related quality of life was associated with decreased antihypertensive adherence. 
 The most frequently prescribed medications used by American older adults, aged 
60 and over, are cardiovascular agents to treat high blood pressure, heart disease and high 
cholesterol including: (a) diuretics 19.9%, (b) beta-blockers 26.4%, and (c) cholesterol-
lowering drugs 44.9% (NCHS, 2010).  The fact that close to 40% of older Americans use 
five or more medications a day reflects the degree of co-morbidity that regularly occurs 
in this age group. Qato et al. (2008) determined community-dwelling older adults are the 
largest consumers of prescription and over the counter medications along with dietary 
supplements, which are often all used concurrently. As a result, an estimated 1 in 25 older 
adults are at risk for significant drug to drug interactions. 
 This study determined the average number of therapeutic drug classes was 4.89 
with a range from 2 to 8. The five most frequently used drug classes were: cardiovascular 
agents (97%), central nervous system agents (94%), nutrients and nutritional agents 
(63%), gastrointestinal (60%) and endocrine and metabolic agents (59%).  These findings 
are similar to what is described in the literature and expands the types of therapeutic drug 
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classes most frequently used in older adults receiving home and community-based 
services. 
Third Hypotheses (H3a and H3b) 
 It was hypothesized that medication regimen complexity would be associated with  
physical and mental health-related quality of life before and after controlling for age, 
gender, education, race, ethnicity, marital status and cognitive status. The data suggested 
that medication regimen complexity was not associated with either physical or mental 
health-related quality of life before and after controlling for the covariates. Medication 
regimen complexity data revealed an average total score of 20.6 with a range from 3 to 
69. The greatest contributor to the MRCI total score was dosing frequency with an 
average score of 13.4 and a range from 2 to 38.  The results support similar findings for 
mean MRCI scores in a similar population (McDonald, et al., 2012). 
 Medication regimen complexity measurement is an emerging area of interest and 
research including: predictive risk for hospitalization and readmission (Elliott, 
O’Callaghan, Paul, & George, 2013; Willson, Greer, & Weeks, 2014), chronic disease 
management (Libby et al., 2013; Rettig, Wood, & Hirsch, 2013), medication adherence 
(Choudry et al., 2011;Witticke, Seidling, Lohmann, Send, & Haefeli, 2013), patient 
preference (Witticke, Seidling, Klimm, & Haefeli, 2012), and decision support 
technology (McDonald et al., 2012).  
Although medication regimen complexity was not associated with either physical 
or mental health-related quality of life, this study advances the use of MRCI tool in 
community-dwelling older adults, which has not been widely studied in home care 
populations. In addition to assessing the total number of medications, quantifying the 
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medication regimen provides a more nuanced way of determining potential challenges 
and risks associated with complex regimens in community-dwelling older adults 
(McDonald et al., 2012).  
Theoretical Rationale 
Wilson and Cleary’s (1995) health-related quality of life conceptual model 
provided the theoretical framework for this interpretation (see Figure 1). This study 
examined components of health-related quality of life by testing Wilson and Cleary’s 
model in community-dwelling older adults who were receiving long-term services and 
supports. According to the Wilson and Cleary model, measures of health exist along a 
continuum moving from biological measures at one end of the continuum to overall 
quality of life at the other, and theorizes bidirectional relationships among the domains. 
The Wilson and Cleary model distinguishes components of health-related quality of life 
from a conceptual standpoint within five domains (biological and physiological factors, 
symptom status, functional status, general health perceptions, and overall quality of life). 
Moving in the model from left to right, the domains of each level become more complex 
for the clinician to determine and measure. The “inputs” as the model progresses, are 
often not within the control of the clinician or health care system (patient preference, role 
of emotional or psychological factors) (Wilson & Cleary, 1995, p.63). The characteristics 
of the individual and the environment are overarching factors that affect all five domains. 
Individual characteristics commonly associated with illness are age, gender, race, 
ethnicity and marital status (Ferrans et al., 2005).  This study proposed to test the 
theoretical linkages of the model components to include: biological and physiological 
factors (medication-related factors: number of medications, number of therapeutic 
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classes, and medication regimen complexity) and overall quality of life (MOS SF-12 
PCS-12 and MCS-12). Individual characteristics selected for inclusion were: (a) age, (b) 
gender, (c) education, (d) race, (e) ethnicity, (f) marital status and (g) cognitive status.  
Regression analysis determined that the number of active medications were predictive of 
physical health-related quality of life before and after controlling for individual 
characteristics (age, gender, education, race, ethnicity, marital status and cognitive 
status). Individuals who take more medications have a decrease in physical health-related 
quality of life. None of the medication-related factors were associated with mental health-
related quality of life before or after controlling for individual characteristics (age, 
gender, education, race, ethnicity, marital status and cognitive status).  
Study Sample Characteristics 
Significant risk factors, based on demographic characteristics, have been  
associated with medication safety in older adults who are aged 65 years and older, have 
less than a high school education, a minority, non-English speaking, have low incomes or 
are unemployed (Health Research & Education Trust, Institute for Safe Medication 
Practices, and Medical Management Association [HRET, ISMP, & MGMA], 2008; 
Lindenberg, 2010). The study sample reflected several of these risk factors to include: (a) 
an average age of 79 years, with a range from 63 to 97 years, (b) 59%  eighth grade 
education or less (n = 72), (c) 68% (n = 84) Hispanic, 35% Black or African American (n 
=35).  
Ancillary Analysis 
Differences in the level of medication complexity based on age were reported. 
Older adults aged 84 years and older demonstrated less medication complexity when 
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compared with adults aged 75 years and younger. These differences may be as a result of 
having chronic illness at a younger age with greater severity of illness that requires more 
medications. In addition, goals of care may shift from aggressive, curative management 
towards an approach of comfort and palliation interventions requiring decreased 
medication use.  
 Additional analysis was conducted to determine whether there were significant 
differences in demographic data related to the main study variables. There were no 
significant differences in either physical or mental health-related quality for age, gender 
or ethnicity.  There were no significant differences in the total number of medications, 
therapeutic drug classes, or medication complexity for gender and ethnicity. 
Strengths and Limitations of this Study 
 This was the first study to examine three medication-related variables, the number 
of active medications, the number of therapeutic drug classes, and medication regimen 
complexity and the association of health-related quality of life in a population at risk for 
potential medication-related issues. The findings from this study contributed to health-
related quality of life research in older adults with long-term health needs. In addition, it 
expanded the growing body of research related to medication regimen complexity 
measurement with strong inter-rater reliability and relevance to clinical practice for 
patients receiving home-based care. The use of secondary data facilitates the generation 
of new knowledge maximizing existing data and is both economical and efficient. 
Limitations 
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 The sample size was small, predominately female (75%), Hispanic (68%), in one 
urban setting which makes it difficult to generalize the findings. Use of secondary 
analysis presents limitations because variables and instruments are defined by the 
primary study. Additional collection of medication data required re-identification of the 
dataset. Cross sectional design allows measurement of variables at a single point in time 
but does not allow for analysis of direction of associations or changes over time.  
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Chapter VI 
Implications, Recommendations and Conclusions 
 Evidence is limited to date linking medication-related variables to include taking 
multiple medications, using multiple therapeutic drug classes and complex medication 
regimens in older adults. There is scant research regarding these characteristics and their 
relationship to health-related quality of life. Findings from this study determined that the 
use of multiple medications was associated with a decreased physical health-related 
quality of life in older adults receiving home and community-based services. Several 
studies have identified community-based older adults as the highest consumers of 
medications and as a result are at higher risk for poor health outcomes that are 
medication-related. Community health nurses can play a significant role in helping 
patients manage complex medication regimens, and reduce potential drug related 
problems to include simplifying medications. Home visits are critical when determining 
specific medication related risk factors may be exist that are not apparent based on patient 
self–reporting alone (Sorensen et al., 2005). 
Implications 
The findings from this study generated several implications for nursing practice 
and education. Additionally, recommendations in the arenas of public policy and future 
research are elucidated from this research. 
Nursing Practice Implications 
 Health plays a central role in nursing and is one of the key metaparadigm 
components (Sousa & Williamson, 2003).  Evaluating health-related quality of life in 
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older adults should be embedded as a standard of nursing practice. Identifying the health 
needs of older adults improves understanding of their responses to disease states as well 
as to prescribed treatments including medications and the impact that disease and medical 
treatments have on daily life activities from the perspective of the individual, rather than 
the nurse. Incorporating health-related quality of life assessment into clinical practice 
provides greater understanding of patients' responses and their self-perception of health to  
include the impact of taking multiple medications (Borglin et al., 2005; Guyatt, et al., 
2007; Singh & Dixit, 2010; Sousa & Williamson, 2003).  
 Community Health Nursing. Plain and simple, caring for older adults who wish 
to remain in their own home, but require long term services and supports (LTSS) to do 
so, is complex and challenging on several levels. Understanding the current LTSS 
landscape and future growth and demand for these services (as a result of  the “Baby 
Boomer” generation growing older), is a call to action for nursing, but significantly so for 
nurses who provide and manage care for older adults in community-based settings. The 
fact that 89% of Americans aged 50 years and older want to remain in their own homes 
for as long as possible and an estimated 5 million older adults are in need of this level of 
care (AARP Public Policy Institute, 2011) posits nursing care in communities in a crucial 
position. Community health nurses (CHNs) can develop, provide and improve care that is 
patient-centric, high quality and cost efficient for older adults who often have complex 
clinical and psychosocially needs often compounded by polypharmacy and medication 
regimen complexity.  
 Community health nurses (CHNs) play a significant role in helping patients 
manage complex medication regimens, and in particular those patients with chronic long-
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term needs that require long term service and supports who wish to remain at home 
(IOM, 2010). A key driver for nursing home admissions is the often the inability to self 
manage complex medication regimens.  
 There are several implications for CHNs that may reduce medication complexity 
and decrease the risk for adverse drug events with the potential to improve a patient’s 
health related quality to include: 
 A first step in reducing medication regimen complexity is to identify patients with 
medication complexity. The ability for clinicians to easily identify complex 
medication regimens through the use clinical support tools such as the MRCI tool 
has not been widely studied in home-based settings. This study advanced the use 
of MRCI tool in home care setting looking at older adults with chronic illness 
 The use of a paper-based MRCI tool is not pragmatic in a community-based 
setting; the development of an electronic MRCI tool would be optimal for practice 
settings (McDonald et al., 2012)  
 Employ the use of medication simplification using a stepwise approach. This 
process involves a thoughtful approach to reducing and simplifying medications 
to include: a) using long-acting forms of medication, b) use of one pharmacy 
provider, c) discard old or discontinued medications, d) provide alternatives to 
medication therapy, e) decrease the use of multiple drug treatment for a single 
condition, f) discontinue or reduce medication whenever possible, and g) schedule 
medications times with daily routines (e.g. brushing teeth, eating a meal) (Home 
Health Quality Improvement Campaign, 2007) 
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 Fostering  inter-professional partnerships with multiple disciplines to include 
medical providers, community pharmacists, social workers, nutritionists, physical 
therapists with a focus for improved communication regarding medication 
management and best practice 
 Consideration and assessment of older adults preference for treatment choice, in 
particular those patients with multiple conditions (co-morbidities); identify the 
patient’s goals of care and align treatment accordingly 
 Explore patient experiences regarding their medication regimens. Providing an 
environment to allow patients to share their perceptions about their medications 
enhances a patient-centered approach to care from the patient’s perspective 
 Identify and administer a health-related quality of life measurement tool as part 
of nursing assessment at regular intervals to measure change over time and 
determine precipitating event of decline 
 
Advanced Practice Nursing.  Home-based primary care services provided to 
community-dwelling older adults by Nurse Practitioners (NPs) is an area with significant 
potential to improve care. By assessing health-related quality of life and medication use, 
NPs  practicing in full scope can work with older adults to establish patient-centric plans 
of care that reflect optimum use of therapeutic agents while minimizing harm and 
improving  health-related quality of life. NPs can ‘unpack’ the different complex layers 
of medication regimens by using a comprehensive approach when assessing the quality of 
medication use in community-dwelling older adults. By using evidence-based practice, 
NPs ensure the rational use of medications that are appropriate based on individual 
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clinical needs in doses that are therapeutic and by simplifying the medication regimen to 
minimize risk and reduce adverse events and ultimately improve health-related quality of 
life outcomes (George & Jacobs, 2011; Lindenberg, 2010; World Health Organization, 
2010).  NPs are well situated to better understand the burden an older adult may 
experience when taking multiple medications at varied times with different requirements 
and how this burden affects their day-to-day routine such as increased urination, 
bothersome side effects and the overall impact on their health-related quality of life. 
Identifying ways to develop and support greater access to NP-led primary care for this 
population needs enhancement. Since the number of active medications was the only 
predictor of physical health-related quality of life, it is imperative to ensure that older 
adults are the taking the absolute minimum number of medications needed to maintain 
health. 
 Enhancing Patient-Centered Care.  Understanding the patient’s perspective and 
their preferences regarding medication-related factors to include the number of 
medications and the frequency they require is an important implication from this study. 
The use of medication should begin with shared-decision making process between the 
patient and the prescriber based on the individual’s preferences and goals of care. Nurses 
practicing in home and community-based settings have an ideal opportunity to educate 
and empower patients to become active participants in their care to include reducing the 
number of medications at less frequent intervals.  
Public Policy Implications 
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 Long Term Services and Supports. The cost of LTSS is expensive for all levels 
of care to include nursing homes, assisted living facilities, and home community-based 
care services (HCBS) (Kaiser Commission on Medicaid & the Uninsured, 2013). LTSS is 
primarily funded by Medicaid with 73% of the costs spent on LTSS provided in nursing 
homes, the most expensive level of LTSS, while only 27% is spent in HCBS, which is the 
least expensive level of LTSS (AARP Public Policy Institute, 2009). Public policy reform 
need to continue to support the expansion HCBS LTSS options that provide patient-
centric quality care that is cost efficient.  
Future Research Recommendations 
 As a result of advances in medical science, many older Americans are living 
longer with chronic conditions including heart disease, diabetes and asthma.  Many 
chronic conditions require long-term medication management and as a result, the focus 
on health-related quality of life will become an increasingly important outcome measure. 
Determining predictors of health-related quality of life, and in particular identifying 
predictors that may be modifiable (e.g. reducing the number of daily medications) to 
improve health-related quality of life need further investigation. Further research is 
required to identify methods to translate health-related quality of life measures into useful 
clinical decision support tools to include a focus on the patient’s perceptions of treatment. 
The recommendations for future research are as follows: 
 
 Conduct a qualitative study to explore patient preference for medication regimen 
characteristics in a sample with characteristics similar to this study sample. The 
aim would be to explore how patients relate their health and use of medication to 
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include the use of alternative treatments to include folk medicine and 
complementary and alternative medicine (CAM). 
 Develop clinical guidelines for older adults with multiple co-morbidities 
particularly in the presence of cognitive impairment aimed at simplifying 
regimens rather than complicating them (American Geriatrics Society, 2012a; 
2012b; Boyd et al., 2005)  
 Hold providers accountable to practice rationale prescribing. Use of rational 
prescribing (Crigger & Holcomb, 2008; Lindenberg, 2010) guides clinicians to 
provide individuals with the appropriate medications to meet their clinical needs, 
at the minimal required doses for the shortest duration possible, provided at the 
lowest costs available 
 Develop automated MRCI and health-related quality of life clinical decision 
support tools that can be standardized for use across multiple health-care settings 
shared among multiple providers 
Conclusions 
Evaluation of medication use is evolving from simply counting the number of 
drugs to more precise medication-related factors such as therapeutic drug class, evidence 
of therapeutic effects and the degree of regimen complexity (Gnjidic et al., 2013).  Older 
adults experience significantly higher rates of adverse drug events (ADRs) and as a result 
experience higher rates adverse outcomes to include falls, hospitalizations, delirium, and 
functional decline (Tinetti et al., 2014).  As a result, health-related quality will often 
decline as well (Henderson et al., 2005; Sorensen et al., 2005). This study contributed to 
the evidence of medication use and health-related quality of life in older adults.0
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Appendix F 
Therapeutic Drug Classification Tool 
 
Therapeutic Drug Class Medication Name (Brand) 
(Example) 
Medication Name 
(Generic) 
(Example) 
1.Cardiovascular Digoxin Lanoxin 
2. Central Nervous System Amitriptyline Elavil 
3. Endocrine & Metabolic Metformin Glucophage 
4. Systemic Anti-Infective Levofloxacin Levaquin 
5. Respiratory  Albuterol Proventil 
6. Hematologic Clopidogrel Plavix 
7. Gastrointestinal Ranitidine Zantac 
8. Renal & Genitourinary Spironolactone Aldactone 
9.  Dermatologic Hydrocortisone Hydrocort 
10.  Ophthalmic & Otic Timolol 0.5% Timoptic 0.5% 
11.  Biologic & Immunologic Methotrexate Rheumatrex 
12.  Nutrients & Nutritional Calcium Citracel 
13. Other Glucosamine Sulfate  
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Appendix G  
Demographic Questionnaire 
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Appendix H 
Letter of Permission Dr. M. Naylor 
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Appendix K 
IRB Approval Visiting Nurse of New York 
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Appendix L 
JAMA Copyright Permission for Wilson & Cleary’s HRQOL Conceptual Model Figure 
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